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SYNOPSIS 
Ce travail présente les résultats médico-économiques d’une étude rétrospective conduite sur la 
cohorte des cas d’adénocarcinomes pancréatiques avancés suivis par la clinique d’Oncochirurgie 
des Hôpitaux Universitaires de Genève ces dix dernières années. Le protocole comparait les 
périodes 1994-98 et 1999-2003 (distinguées sur la base de la disponibilité de molécules modernes 
telles que la gemcitabine). 
Survie : les patients de la seconde période ont survécu significativement plus longtemps que 
ceux de la période précédente (médiane de 8.7 versus 7.1 mois, probabilité de survie à 1 an de 
40% versus 14% ; log-rank p=0.012), sans augmentation significative des épisodes 
d’hospitalisation ; 
Coûts : ce bénéfice de survie s’est accompagné d’une augmentation significative des dépenses 
ambulatoires (médiane de 8'537 versus 5'005 CHF ; p=0.006). 
Ces résultats sont à interpréter avec réserve au vu des limitations méthodologiques de l’étude. 
Ils sont cependant corroborés dans la littérature actuelle par les données récentes de plusieurs 
essais cliniques randomisés. 
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RESUME 
L’adénocarcinome pancréatique représente environ 90% des cas d’atteinte maligne du pan-
créas. Avec une incidence moyenne de 11.7 cas pour 100'000 de 1995 à 1998 à Genève, il repré-
sente environ 2 à 3% des diagnostics de néoplasies. Tous stades confondus, les taux de survie à 1 
an et à 5 ans sont respectivement de 20% et de moins de 5%, tandis que la survie médiane après 
résection n’est que de 13 à 20 mois. Pire encore, la survie médiane des cas métastatiques ainsi 
que des cas loco régionalement avancés au diagnostic ne dépasse pas 3 à 6 mois et 6 à 10 mois, 
respectivement. Ce pronostic catastrophique explique que la mortalité annuelle du carcinome du 
pancréas se rapproche fortement de son incidence, puisque moins de 20% des patients se présen-
tent avec une maladie macroscopiquement limitée à l’organe lors du diagnostic initial : approxi-
mativement 40% souffrent d’une maladie loco régionalement dépassée, 40% présentent des 
métastases viscérales –principalement hépatiques–, et 35% des implants tumoraux péritonéaux 
(certains patients appartenant à deux, voire à ces trois catégories mutuellement non exclusives). 
D’un point de vue thérapeutique, le seul traitement curatif repose sur une pancréatectomie, la 
plus souvent partielle, qui ne peut être raisonnablement proposée qu’aux patients présentant une 
maladie macroscopiquement limitée (stades I et II). Une radiothérapie adjuvante est parfois 
offerte à distance de la chirurgie dans l’espoir d’un meilleur contrôle locorégional. Malheureuse-
ment, et en raison d’une symptomatologie frustre et souvent tardive, la majorité des patients sont 
diagnostiqués à des stades avancés. Les possibilités thérapeutiques se limitent alors à des inter-
ventions palliatives de dérivation biliaire et/ou digestive si nécessaire, et à des traitements de 
chimiothérapie/radiothérapie. Concernant la chimiothérapie, le 5-fluorouracile était considéré 
comme le traitement de choix jusqu’au milieu des années 90, même si quelques études randomi-
sées contrôlées n’avaient pu mettre en évidence de bénéfice significatif par rapport à un traite-
ment de soutien seul en termes de survie. 
L’introduction de la gemcitabine dans cette indication, en Suisse au deuxième semestre de 
1998, puis de l’oxaliplatine, apporta un second souffle à la prise en charge palliative de ces 
patients, comme peut en témoigner l’augmentation exponentielle des études cliniques de phase I 
et II ces dernières années, cherchant à définir les régimes de drogues modernes les plus efficaces 
et surtout les moins toxiques. D’une manière générale, ces innovations thérapeutiques ne se sont 
pas traduites de manière fulgurante en termes d’indicateurs classiques que sont la survie médiane 
et la survie à 1 an, n’améliorant la situation que de manière marginale quoique cependant statisti-
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quement significative. En réalité, la véritable amélioration a plutôt concerné la symptomatologie 
de ces patients et l’impact de la maladie sur leur qualité de vie en termes d’index de performance 
et de soulagement des douleurs. En effet, les essais randomisés contrôlés comparant des 
protocoles modernes à base de gemcitabine au précédent traitement de référence à base de 5-fluo-
rouracile ont mis en évidence la supériorité significative des premiers sur le second en termes de 
bénéfice clinique (Clinical Benefit Response) sans augmentation significative des effets secondai-
res indésirables sévères. Ainsi, l’attitude de la majorité des oncologues a passablement évolué 
depuis l’introduction de la gemcitabine, passant d’une tendance à l’abstention thérapeutique ou à 
la prescription peu convaincue de 5-fluorouracile, à la prescription de molécules modernes plus 
fréquente car reconnue comme efficace en termes de bénéfice clinique. D’un point de vue plus 
classique et quantitatif, et selon les données de la littérature actuelle que nous résumons en pre-
mière partie de notre travail, les patients atteints d’un carcinome du pancréas dépassé pouvaient 
espérer une survie médiane d’environ 5 à 7 mois sous traitement de 5-fluorouracile seul. Cette 
espérance est actuellement d’environ 7 à 10 mois sous traitement de gemcitabine. Concernant les 
associations de gemcitabine à d’autres agents chimiothérapeutiques classiques tels que le cispla-
tine ou l’oxaliplatine, les espoirs fondés sur les résultats de nombreuses études de phase II ont été 
très récemment mis à mal par la présentation au congrès de l’ASCO 2004 des conclusions déce-
vantes de plusieurs essais cliniques randomisés de phase III, ne parvenant pas à démontrer de 
supériorité significative des régimes d’association sur les protocoles à base de gemcitabine seule 
en termes de survie. Les résultats définitifs de deux études de phase III comparant une association 
de gemcitabine et de Xeloda (formulation orale du 5-fluorouracile se rapprochant d’une infusion 
continue) à la gemcitabine seule devraient être disponibles dans un avenir proche (protocoles 
SAKK et MRC). 
Dans ce contexte, il nous a paru intéressant de mener une étude rétrospective1 sur le sujet en 
analysant l’ensemble des cas de carcinomes du pancréas ayant été suivis par le service 
d’oncochirurgie des Hôpitaux Universitaires de Genève depuis octobre 1993 jusqu’en octobre 
2003, soit sur la dernière décennie. Notre intention était davantage de comparer deux périodes 
que deux traitements précis, c’est-à-dire une période de 1993 à 1998 avant l’introduction de la 
gemcitabine, et la période suivante de 1999 à 2003, en posant l’hypothèse initiale selon laquelle 
le changement d’attitude des oncologues relatif à la prescription de chimiothérapie dans cette 
                                                     
1 Protocole de recherche formellement approuvé par le Comité d’éthique des Hôpitaux Universitaires de Genève 
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indication se traduirait par une différence significative en termes de survie et d’indicateurs gros-
siers de qualité de vie tels que la durée d’hospitalisation. De plus, au vu des considérations politi-
ques, assécurologiques et économiques actuelles qui remettent en question les pratiques 
médicales modernes de la plupart des pays développés, nous avons voulu étendre l’analyse à une 
dimension médico-économique et comparer les deux périodes en termes de dépenses pour 
l’hôpital liées au cancer du pancréas avancé. 
METHODOLOGIE 
Pour ce faire, nous avons tout d’abord obtenu du Registre Genevois des Tumeurs les informa-
tions épidémiologiques relatives à la décennie analysée. Puis nous avons répertorié l’ensemble 
des cas de carcinome du pancréas ayant bénéficié d’une consultation par le service 
d’oncochirurgie, et inclus les patients suivis auprès de ce dernier durant une proportion significa-
tive de la maladie. Nous avons ensuite constitué une base de données comprenant des informa-
tions démographiques ainsi que les caractéristiques et jalons de la maladie : date de diagnostic 
(définie comme la date d’entrée du séjour hospitalier ayant mené à ou confirmé le diagnostic) ; 
facteurs pronostiques (âge, stade, taille de la tumeur, site primitif et index de performance au dia-
gnostic) ; nombre et durée d’hospitalisations (catégorisées en traitement, complication du traite-
ment, complication de la maladie et autres) ; détails du traitement (opérations, radiothérapie, 
nombre de lignes, de cycles et doses de chimiothérapie). En ce qui concerne la définition des 
groupes, nous avons classé chronologiquement les patients retenus en fonction de la date du 
diagnostic de la maladie oncologique, puis considéré la première ligne de chimiothérapie reçue, 
en excluant les modalités combinées de radio- et chimiothérapie. Nous avons alors retenu comme 
date charnière pour la définition des deux périodes la date du premier cycle de gemcitabine pour 
le premier patient recevant ce médicament en première intention. En outre, avec l’aide du l’Unité 
d’Information Médico-Economique de l’hôpital, nous avons calculé sur la base du système de 
comptabilité analytique des H.U.G. le coût de tous les séjours hospitaliers (H.U.G., Beau-Séjour 
et CESCO) et des visites ambulatoires en oncochirurgie pour chacun des patients inclus dans 
l’étude. De plus, nous avons calculé un coût moyen par jour d’hospitalisation pour les séjours 
dans des établissements de convalescence (Joli-Mont, Montana, Loëx, Génolier etc.) afin de les 
inclure dans notre estimation du total des coûts. En raison de la période de temps étendue recou-
verte par notre étude, l’ensemble des coûts a été annualisé en unités 2002 au moyen de facteurs 
de pondération spécifiques afin de prendre en compte l’augmentation des coûts de la santé et de 
permettre une comparaison entre les deux groupes. La quasi-totalité des patients considérés ayant 
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été suivis intégralement par le service d’oncochirurgie de l’Hôpital Cantonal en ambulatoire, il 
est peu probable que des dépenses importantes aient été encourues en dehors de cette 
consultation. En conséquence, et étant donné que leur détermination aurait été largement aléatoire 
compte tenu du design rétrospectif du protocole, les coûts extrahospitaliers (à ne pas confondre 
avec les coûts ambulatoires) n’ont pas été considérés dans l’analyse. 
Des analyses statistiques classiques ont alors été conduites sur la base des données récoltées, 
avec un seuil de signification fixé à 0.05 : l’objectif primaire consistait en une analyse de survie, 
effectuée selon la méthode de Kaplan et Meier afin de tenir compte des patients perdus de vue et 
des patients toujours vivants au moment de l’analyse. Les objectifs secondaires comprenaient une 
analyse de durée d’hospitalisation, ainsi qu’une comparaison économique des coûts pour l’hôpital 
au cours des deux périodes considérées. 
A noter que si notre intention initiale était de considérer les cas de carcinome pancréatique 
tous stades confondus, nous avons finalement décidé de restreindre l’analyse aux stades III et IV, 
respectivement loco régionalement avancés et métastatiques, pour des raisons d’homogénéité : les 
deux groupes issus de la cohorte globale se sont en effet révélés lors de l’analyse des facteurs 
pronostiques significativement différents en termes de proportion de stades I et II versus III et IV, 
introduisant un important biais potentiel pour l’analyse de survie : il est bien démontré que les 
patients bénéficiant d’une résection survivent significativement plus longtemps que les patients 
diagnostiqués directement à un stade palliatif, et que ces deux catégories correspondent à deux 
profils différents et incomparables de biologie tumorale. Une solution potentielle eût été de défi-
nir pour les patients réséqués une date de rechute, et de ne considérer que leur survie en situation 
palliative. Cependant, la définition d’une telle date s’avère extrêmement hasardeuse étant donné 
l’absence de protocole de suivi précis et l’absence de corrélation entre les marqueurs biologiques 
et la charge tumorale en termes pronostiques. D’une manière générale, l’établissement d’un stade 
pronostique en situation de récurrence étant un non-sens en oncologie, il aurait été difficile 
d’apprécier l’homogénéité de groupes ainsi définis. Dans ce contexte, nous avons en définitive 
conduit les analyses de survie ainsi que les calculs médico-économiques sur une population res-
treinte aux stades III et IV uniquement. 
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RESULTATS 
Avec un total de 84 malades, notre échantillon représentait environ 16% de l’ensemble des cas 
de carcinome du pancréas ayant été déclarés dans le canton durant la période 1994-2001 (données 
épidémiologiques non disponibles pour 2002 et 2003). La date pivot retenue correspondant au 22 
décembre 1998, nous avons initialement déterminé deux groupes comprenant 39 patients pour la 
première période (Groupe A) et 45 patients pour la seconde période (Groupe B). L’analyse de ces 
patients en termes de facteurs démographiques et pronostiques n’a pas révélé de différences 
significatives pour le sexe, la taille de la tumeur, sa localisation et l’index de performance au dia-
gnostic initial. L’âge au diagnostic était par contre significativement plus jeune dans le groupe A. 
Mais surtout les deux groupes se sont avérés significativement différents en termes de stade au 
diagnostic, les proportions respectives de stades I et II (patients résécables) et de stades III et IV 
(maladies dépassées) se montant à 44%/56% versus 22%/78%, respectivement pour les groupes 
A et B (p=0.037). Pour les raisons citées précédemment, nous avons alors décidé de conduire les 
analyses ultérieures sur une cohorte restreinte aux cas loco régionalement avancés ou métastati-
ques au diagnostic, dont l’évolution clinique peut être considérée comme homogène. Les groupes 
finaux comprenaient 22 patients pour le groupe A et 35 pour le groupe B. Une comparaison sta-
tistique en termes de facteurs démographiques et pronostiques n’a pas révélé de différence statis-
tiquement significative excepté la persistance d’un écart d’âge au diagnostic initial (médiane de 
59 ans pour le groupe A contre 66 pour le groupe B, p=0.005). 
En ce qui concerne l’objectif primaire de l’étude, une analyse de survie a révélé une différence 
significative entre les deux groupes, avec une médiane de survie de 7.1 et 8.7 mois et une proba-
bilité de survie à un an de 14% et 40% pour le groupe A et le groupe B, respectivement (log-rank 
p=0.012, hazard ratio=0.52, intervalle de confiance à 95% 0.23-0.84). Les patients ayant survécu 
plus d’une année, soit les « survivants à long terme », sont majoritairement responsables de cette 
observation, comme en témoigne l’écartement des courbes au-delà de 300 jours. Cependant, un 
recouvrement des intervalles de confiance à 95%, expliqué par la petite taille des effectifs, nous 
pousse à interpréter ces résultats plutôt comme une tendance qu’une différence formellement 
significative (intervalles de confiance à 95% pour la probabilité de survie à un an : 3-35% contre 
24-58%, respectivement). Ces valeurs sont compatibles avec les chiffres moyens publiés dans la 
littérature. Une analyse de la quantité de chimiothérapie administrée aux patients des deux grou-
pes a également révélé une différence significative, avec une médiane de 1 dose administrée par 
patient pour le groupe A contre 14 pour le groupe B (p=0.0002). 
 - 8 - 
Une analyse du nombre total de journées d’hospitalisation n’a pas révélé de différences signi-
ficatives entre les deux groupes. Dès lors, une analyse comparant les deux groupes en termes de 
survie ambulatoire (durée des séjours en hôpital retranchée de la survie totale) a logiquement 
confirmé le bénéfice de survie initialement observé pour le groupe B (médiane de 144 jours hors 
hospitalisation pour le groupe A contre 199 pour le groupe B, P=0.013, hazard ratio=0.52, inter-
valle de confiance à 95% 0.24-0.84). Si l’on accepte ce paramètre comme une appréciation gros-
sière de la qualité de vie, nous concluons prudemment que les gains observés en termes de survie 
avec les traitements actuels ne semblent pas être grevés d’une morbidité excessive : en effet, la 
majorité des séjours hospitaliers pour les patients inclus dans l’étude correspondaient à des situa-
tions de complications sévères liées à la maladie, telles que des obstructions biliaire ou digestive 
sanctionnées chirurgicalement, ou à des situations de soins de confort en fin de vie. 
L’analyse du nombre de consultations en ambulatoire au service d’oncochirurgie pour traite-
ment ou suivi a elle aussi révélé une différence significative entre les deux groupes, les patients 
du groupe B affichant une médiane de 28 visites contre 21 pour le groupe A (p=0.007). Ces 
résultats sont à mettre en relation avec les observations médico-économiques correspondantes : 
une comparaison globale des deux groupes n’a pas révélé de différence significative en termes de 
total des coûts hospitaliers. Par contre, une stratification plus fine en coûts reliés aux hospitalisa-
tions et coûts reliés aux visites ambulatoires a corroboré les résultats précédemment exposés : les 
deux groupes n’ont pas présenté de différence significative en termes de coûts reliés aux hospita-
lisations, mais les patients du groupe B ont coûté significativement plus cher en visites 
ambulatoires (médiane de 5'005 CHF pour le groupe A versus 8'537 pour le groupe B, p=0.006). 
La faible proportion du total des coûts représentée par ces dernières (6% pour le groupe A versus 
15% pour le groupe B) peut expliquer que cette différence ne se reflète pas dans l’analyse glo-
bale. De même, l’augmentation de cette proportion entre les deux périodes est à mettre en relation 
avec l’augmentation de la durée de survie et du nombre de chimiothérapies administrées, de 
même qu’avec l’augmentation du coût moyen des drogues correspondantes. 
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DISCUSSION 
Si nos résultats sont indéniablement sujets aux biais classiques inhérents aux analyses rétros-
pectives et à l’importance de la période de temps considérée, ils n’en suggèrent pas moins une 
conclusion intéressante, dont la portée locale et exploratoire mériterait d’être confirmée prospec-
tivement sur une échelle plus large : considérées dans leur globalité, nos observations suggèrent 
qu’il existe une faible proportion de patients atteints de carcinome pancréatique avancé dont la 
biologie tumorale plus favorable pourrait se traduire par une meilleure susceptibilité à la chimio-
thérapie. Ce sont ces patients qui semblent bénéficier majoritairement des nouvelles molécules, et 
il n’est désormais plus rare de suivre des survivants à long terme pendant parfois 2 à 3 ans, voire 
même davantage. Étant donné que la différence de survie observée est une différence de survie 
ambulatoire, on peut supposer à première vue que ce bénéfice s’accompagne d’un certain main-
tien de la qualité de vie. De plus, et par voie de conséquence, à cette prolongation correspond 
également une multiplication des consultations de suivi et de traitement loco régionalement, 
entraînant un surcoût ambulatoire certain quoique modeste. Si dans le cas précis du carcinome 
pancréatique avancé ce surcoût n’est pas très impressionnant en raison de la survie médiane très 
limitée des patients concernés (quoique certains survivants à long terme inclus dans notre étude 
aient atteint une fourchette de coûts ambulatoires allant de 20'000 à 50'000 CHF), une extrapola-
tion à la population suisse dans son ensemble, et surtout à d’autres pathologies malignes bien plus 
prévalentes, permet de replacer cette problématique au centre des préoccupations économiques et 
politiques actuelles. A cet égard, le cas du carcinome colorectal métastatique est édifiant, puisque 
la survie médiane observée a quasiment doublé sur les dix dernières années : estimée entre 10 et 
12 mois au début des années 90, elle dépasse actuellement les 20 mois avec les associations chi-
miothérapeutiques les plus modernes. A ce doublement de l’espérance de vie médiane des 
patients s’est associée une augmentation de près de 340 fois du prix moyen des médicaments, 
passant d’environ 100-300 dollars pour le 5-fluorouracile à environ 20’000-30'000 dollars pour 
les nouvelles thérapies ciblées (bevacizumab, cetuximab), et ce en considérant uniquement les 
huit premières semaines de traitement ! 
L’évolution de l’oncologie moderne illustre donc particulièrement bien le prix à payer pour 
repousser davantage les limites de la maladie : si le progrès médical n’est certainement pas à lui 
tout seul responsable de l’augmentation des coûts de la santé, il en participe indéniablement, tant 
par la mise à disposition de molécules toujours plus ciblées, plus complexes à développer et pres-
que invariablement plus chères que par l’augmentation de survie qu’elle rendent possible pour 
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des patients nécessitant des soins –soit une consommation de ressources médicales– réguliers. 
Compte tenu de l’impact possible qu’auront les mesures politiques actuellement en chantier en 
Suisse sur la disponibilité de ce progrès au plus grand nombre à moyen terme, il est de notre point 
de vue nécessaire d’impliquer au plus vite tous les acteurs du secteur –législateur, fournisseurs de 
soins, payeurs, et avant tout, patients– dans une réflexion plus transparente et consensuelle. 
PLAN DU TRAVAIL 
Après une introduction épidémiologique et clinique générale à la pathologie maligne du pan-
créas, nous mènerons une revue systématique de la littérature concernant la prise en charge loco 
régionalement du cancer pancréatique avancé et présenterons les associations médicamenteuses 
les plus prometteuses évaluées ces dernières années dans le cadre du traitement de cette patholo-
gie. Ensuite, nous introduirons la problématique de notre étude, présenterons notre méthodologie 
ainsi que nos résultats, que nous commenterons enfin sur les plans méthodologique, clinique et 
médico-économique. 
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INTRODUCTION TO PANCREATIC CANCER 
EPIDEMIOLOGICAL CONSIDERATIONS 
Pancreatic ductal adenocarcinoma is the most common malignant disease of the exocrine pan-
creas and accounts for approximately 90% of pancreatic cancer cases. There are about 30,000 
newly diagnosed cases and approximately the same number of deaths from this disease annually 
in the United States. Pancreas cancer accounts for 2% to 3% of all malignant neoplasms diag-
nosed worldwide [1]. All stages combined, 1-year and 5-year survival rates are 20% and less than 
5%, respectively. Median survival time is 13 to 20 months after pancreatic resection with less 
than 10% to 20% of patients being long-term survivors (i.e. surviving more than one year); it is 3 
to 6 months and 6 to 10 months for patients with metastatic and locally advanced disease, respec-
tively. Unfortunately, at the time of presentation, less than 20% of patients have a disease macro-
scopically confined to the organ: approximately 40% have locally advanced disease, 40% show 
visceral metastases and 35% show peritoneal implants [2] (the latter categories being not mutu-
ally exclusive). This explains why, whilst being the ninth cancer in men and the eighth in women 
in terms of frequency, pancreatic cancer is the fourth cause of cancer deaths in both sex (US data) 
[1], causing around 200,000 deaths yearly in the world. Data from the National Cancer Database 
report a peak age of occurrence of 70 to 79 years [3]. 
The two biggest risk factors for pancreatic cancer are ageing and smoking. Other predisposing 
factors include occupational exposure to leather tanning and machine shops [4]. Patients with 
hereditary chronic pancreatitis are at increased risk. The estimated risk for this specific 
population to age 70 may be as high as 40%, several decades after onset of the initial pancreatitis 
[5]. This familial syndrome of autosomal dominant inheritance and of 80% penetrance rate is 
characterized by recurrent episodes of pancreatitis occurring early in childhood and recurring 
throughout life. Its incidence is uncertain, but as many as 5% of patients experiencing an episode 
of pancreatitis may have the hereditary type of the disease. In hereditary pancreatitis, uninhibited 
mutated trypsin [6] initiates a proteolytic cascade within the pancreas itself, leading to 
autodigestion and acute pancreatitis. In patients with chronic pancreatitis from other causes, the 
risk of pancreatic adenocarcinoma has been estimated between 2 and 15 times greater than in 
control people [7, 8]. 
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Familial pancreatic cancer is another autosomal dominant condition with an unidentified 
causative mutation. Diagnostic criteria are the following: two or more first degree relatives with 
pancreatic ductal adenocarcinoma, one first degree relative with early-onset disease (less than 50 
years at the time of diagnosis) or two or more second degree relatives with the disease, one of 
whom having experienced early-onset cancer. Other genetic causes of pancreatic cancer, associ-
ated with an increased risk of invasive skin melanoma, include mutations of the CDKN2 [9], 
p16INK4 [10] and BRCA1/2 [11, 12] tumor suppressor genes. 
PATHOLOGY 
The TNM classification system for pancreatic tumors was modified in 2002 [13]: 
TNM Classification and 
Staging System 
Characteristics 
Tx Primary tumor not assessable 
T0 No evidence of primary tumor 
Tis Carcinoma in situ 
T1 Tumor limited to the pancreas, <2cm in diameter 
T2 Tumor limited to the pancreas, >2cm in diameter 
T3 
Tumor extending beyond the pancreas but without involving the 
celiac axis or the superior mesenteric artery 
T4 
Tumor involving the celiac axis or the superior mesenteric artery 
(unresectable primary tumor) 
Nx Regional lymph nodes not assessable 
N0 Regional lymph nodes not involved 
N1 Regional lymph nodes involved 
Mx Distant metastasis not assessable 
M0 No distant metastasis 
M1 Distant metastasis/es 
Stage 0 Tis, N0, M0 
Stage I T1-2, N0, M0 
Stage II T3, N0-1, M0 
Stage III T4, any N, M0 
Stage IV Any T, any N, M1 
This revised classification is clinically more coherent in terms of prognostic: contrasting with 
previous iterations, stages I and II now correspond to resectable tumors and stages III and IV to 
unresectable ones, respectively locally advanced and metastatic. 
Based on National Cancer Database registry data, 78% of pancreatic adenocarcinomas arise in 
the head region, while 11% arise in the body and 11% in the tail [3]. Because of their proximity 
to the common bile duct, patients with a tumor arising in the pancreatic head commonly present 
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at earlier stages (longest axis usually 2 to 3.5 cm) with painless jaundice caused by bile duct 
obstruction. Conversely, patients with a tumor arising in the body and/or tail region present at a 
later stage (longest axis usually 5 to 7 cm), typically with pain caused by malignant infiltration of 
neural and retroperitoneal structures. Accordingly, the ratio of limited to advanced disease (stage 
I/stage IV) is 0.7 for tumors arising in the head region, but only 0.24 for body tumors and 0.1 for 
tail tumors [3]. 
From a practical viewpoint, locally advanced pancreatic cancer is defined as an unresectable 
tumor without evidence of distant metastases. Generally, one of the following features accounts 
for surgical unresectability [14]: 
- Extensive peripancreatic lymph node involvement; 
- Encasement or occlusion of the superior mesenteric vein or superior mesenteric vein/portal 
vein confluence; 
- Direct involvement of the superior mesenteric artery, inferior vena cava, aorta or celiac 
axis. 
DEVELOPMENT AND GENETICS OF PANCREATIC CANCER 
Regarding the pancreatic carcinoma precursor lesion, some clinical studies have demonstrated 
a chronological sequence between pancreatic duct lesions and invasive carcinomas and thus 
established that the former were truly precursors to the latter [15, 16]. The Pancreatic Intraepithe-
lial Neoplasia (PanIN) nomenclature for early lesions was standardized in 1999 based on this 
sequence. It grades lesions on a 1 to 3 scale, grade 1 showing the least architectural and cytologi-
cal atypia and grade 3, equivalent to carcinoma in situ, showing the most [17]. 
From a molecular genetic perspective, activating point mutations in proto-oncogene K-ras 
(seen in 90% of pancreatic adenocarcinoma and in roughly 30% of all cancers, including colon, 
lung and bladder carcinoma) and over expression of proto-oncogene Her2/neu (a member of the 
epidermal growth factor receptor family) are seen in the earliest precursor lesions and are thought 
to be early genetic events in the development of pancreatic carcinoma [8]. K-ras protein normally 
goes through a cycle of GTP-GDP exchange and is involved in signal transduction of extra cel-
lular mitogenic stimuli, thus promoting cell growth and proliferation. Oncogenic K-ras is unable 
to hydrolyze bound GTP, resulting in constant K-ras signaling that cannot be switched off [18]. 
This is followed by papillary hyperplasic lesions. Inactivation of the p16 tumor suppressor gene, 
which stops cellular proliferation, seems to occur at this stage (PanIN 2 and 3), and the p53 (seen 
in 50-70% of pancreatic tumors [19]), DPC4 (or SMAD4) and BRCA2 genes are apparently lost 
in even later stages of the neoplasic process (almost exclusively in PanIN 3) [15, 16, 20]. The 
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timing of other tumorigenic activities (DNA methylation, telomerase and matrix metalloprotein-
ase activation) and a number of low-frequency genetic alterations (inactivation of the MKK4, 
STK11, ALK5 and TGFBR2 tumor suppressor genes) has not been described yet. 
DIAGNOSIS AND STAGING 
Initial symptoms of pancreatic carcinoma include pain, jaundice, anorexia, early satiety, 
weight loss, depression and new-onset diabetes. Among them, painless jaundice offers the best 
prognosis, with more than 50% of patients being eligible for resection based on preoperative 
assessment. Conversely, 80% to 90% of patients presenting with pain are declared unresectable, 
since this almost invariably results from celiac plexus invasion. Weight loss is due on the one 
hand to interruption of gastrointestinal flow of bile and pancreatic juice, and on the other hand to 
the typical catabolic state accompanying aggressive malignancies. Jaundice is most commonly 
obstructive as a result of a tumor arising in the head of pancreas and obstructing the intra pancre-
atic bile duct. Other clinical signs of the disease include hepatomegaly, a palpable gallbladder 
(Courvoisier’s sign, seen in 40% of cases), cachexia, Troisier’s sign (involved Virchow’s node) 
and ascites [18]. 
Currently, no serum marker offers enough sensitivity or specificity to be employed as an 
effective early diagnosis or screening tool. CA 19-9 serum level is the most sensitive and specific 
one, but it is almost never positive in small, i.e. curable tumors [21]. Furthermore, benign causes 
of bile duct obstruction and other gastrointestinal cancers may also raise serum CA 19-9 levels. 
On the other hand, CA 19-9 dosages are commonly used in the follow-up of patients. 
As already mentioned, a number of genetic lesions are associated with pancreatic adenocarci-
noma, including mutations of the K-ras (90%), p16 (80%), p53 (50%) and DPC4 (50%) genes 
[22]. Among them, however, none has demonstrated enough sensitivity nor specificity to serve as 
a discriminating diagnostic tool, even the most extensively studied K-ras mutation [17]. Potential 
for gene therapy is being currently intensively explored, for instance by replacement of tumor 
suppressor genes, use of antisense oligonucleotides, immunotherapy or gene-directed enzyme 
prodrug therapies [23]. So far, results have been rather disappointing: for example, a combination 
regimen of gemcitabine plus tipifarnib (farnesyltransferase inhibitor) has not been shown superior 
to gemcitabine alone in terms of overall survival time in a recent randomized phase III trial [24]. 
The role of diagnostic imaging in the assessment of a suspected pancreatic carcinoma is, first, 
to establish the diagnosis of a malignant lesion, and second to assess resectability. CT scanning is 
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the first-choice imaging technique, since it assesses pancreatic parenchymal lesions and provides 
information about the ductal system, local extension, the presence or absence of biliary dilation, 
regional lymph nodes status and the status of other target organs of distant metastases [4]. Small 
tumors, i.e. curable lesions, may fall below the detection level of this standard imaging technique. 
However, the sensitivity of dual-phase spiral CT scanning for identifying unresectable tumors 
may be as high as 90% [25], although less optimistic results have been published in a recent 
review [26] (i.e. about 75%). Thus, in patients with radiological absence of the above mentioned 
unresectability criteria, surgeons may still be confronted to advanced tumors at the time of 
laparotomy [27, 28]. 
Magnetic resonance imaging does not seem to be more sensitive than CT scanning for the 
diagnosis of pancreatic cancer, but its specificity may be superior, allowing for the distinction of 
a clear mass in patients whose CT assessment can only evidence indeterminate enlargement of 
the pancreatic head. However, its ability to discriminate resectable lesions from unresectable 
tumors has not been proven superior to CT scan imaging [29]. 
ERCP adds generally little to diagnostic staging, but it remains indicated for patients present-
ing with biliary obstruction when an ampullary lesion is suspected. On the other hand, endoscopic 
ultrasound may be the most accurate imaging test for the diagnosis of pancreatic cancer. This 
technique seems especially effective in identifying tumors less than 3 cm in diameter, which may 
be missed on CT scans [30]. It is also a highly effective modality to obtain a tissue diagnosis with 
a very low complication rate, minimizing the risk of tumor dissemination (which is occasionally 
attributed to percutaneous needle biopsy). 
Finally, laparoscopic staging is performed in some centers, since it may prevent unnecessary 
laparotomy by detecting occult micro metastasis in 30% of patients [26, 31]. However, when 
laparoscopy is performed on patients thought to have resectable disease according to high-quality 
CT criteria, the proportion of unresectability findings is in the range of 4% to 13% only, as 
reviewed by Pisters et al. [26]. This observation does not support the use of laparoscopy as a rou-
tine staging procedure. 
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Nevertheless, the condition for defining an adequate treatment strategy relies on an accurate 
tissue diagnosis, which is unfortunately often difficult to obtain, despite clinical or radiological 
evidence of pancreatic malignancy. Indeed, paucity of cancer cells in the diagnostic sample as 
well as intense local fibrosis associated with the disease often challenge histological diagnosis 
[17]. Hence, many patients enter treatment without a formal tissue diagnosis (depending on cen-
ters). Also, presentation and radiological findings in chronic pancreatitis and pancreatic cancer 
overlap in a significant proportion of cases. Thus, as much as 5 % to 10% of patients with sus-
pected pancreatic cancer may turn out to suffer from chronic pancreatitis upon examination of the 
resection specimen. Conversely, around 5% of patients with presumed chronic pancreatitis who 
undergo resection end up with a final histological diagnosis of pancreatic cancer. This diagnostic 
dilemma places a significant degree of stress on surgical decision-making, since pancreatic resec-
tion may have a mortality rate of as much as a 5% and a morbidity rate of about 40% [18]. 
TREATMENT OVERVIEW AND SURVIVAL 
RESECTABLE PANCREATIC CANCER 
The only curative treatment of pancreatic adenocarcinoma is surgical resection, i.e. either a 
pancreaticoduodenectomy for lesions arising in the head region or a left splenopancreatectomy or 
sometimes a total pancreatectomy for lesions arising in the body and tail regions. Surgery is not 
proposed if liver or peritoneal metastases are present at the time of diagnosis or if metastases are 
identified in lymph nodes that are not routinely removed as part of the procedure. In the absence 
of distant metastases, resectability depends on major vascular invasion by the tumor. However, 
advances in surgical technique now allow for en bloc resection of the superior mesenteric 
vein/portal vein confluence for isolated tumor extension although it is not clear whether such a 
procedure shall have a positive influence on the overall survival time [32]. Data support a current 
mortality rate for pancreaticoduodenectomy in the range of 1% to 5% [33, 34], strongly contrast-
ing with the 30-day mortality rate of this procedure in the 1960s and 1970s, which approached 
25%. Unfortunately, despite evident progresses in diagnostic and staging modalities and 
improved surgical management, there has not been any dramatic improvement in overall survival 
time for patients diagnosed with pancreatic carcinoma over the past two decades [35]. 
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Adjuvant therapy 
Patterns of failure after surgical resection are well established: loco regional recurrence 
develop from persistent intra abdominal microscopic disease as well as hepatic or peritoneal 
metastases from persistent micro metastatic disease [36]. The principles of adjuvant therapy sug-
gest trying and eradicating this persistent microscopic disease before additional proliferation into 
clinically evident recurrence. 
In a 2003 review, Abrams et al. point out recent evidence regarding adjuvant therapy in 
resectable pancreatic cancer [37]: in 1985, an important although controversial study by the 
Gastrointestinal Tumor Study Group prospectively randomized post-pancreatectomy patients to 
either observation (control arm) or to split course radiotherapy (40 Gy in 2 20-Gy sequences, 20 
fractions and 6 weeks) with bolus 5-FU (500 mg/m2 intravenously daily on each of the first three 
radiation days of each 20 Gy sequence), followed by bolus 5-FU once weekly for 2 years after 
completion of radiotherapy [38]. This study evidenced a positive effect this adjuvant protocol, 
since median and long-term survival time were both significantly improved in the latter group of 
patients (20 months versus 11 months, P=0.03, and 19% versus 5% 5-year survival probability, 
respectively). Yet, the results of this study were contested since less than fifty patients entered the 
trial. A follow-up GITSG study registered an additional 30 patients to receive adjuvant 5-FU and 
radiation therapy [39]. This group of patients showed a median survival time of 18 months and a 
5-year survival probability of 17%. 
The European Organization for Research and Treatment of Cancer (EORTC) recently com-
pleted a randomized phase III trial evaluating adjuvant chemo radiation versus observation in 218 
patients having undergone curative-intent resection of the pancreatic head and carcinomas of the 
periampullar region [40]. The chemo radiation regimen was similar to the one given in the 
GITSG trial, but without maintenance therapy. Survival data showed improvements in the chemo 
radiation arm, with a median survival time of 24.5 months versus 19 months and a 5-year survival 
probability of 28% versus 22%, however not reaching statistical significance. Although the 
authors concluded that routine use of adjuvant chemo radiotherapy should not become a standard 
treatment in resectable pancreatic cancer, their radiation schedule (40 Gy in 2 20-Gy sequences) 
was not the most effective one. Overall however, chemo radiotherapy as an adjuvant treatment 
after resection of pancreatic cancer still remains controversial in terms of survival time benefit 
[41]. A randomized trial by the European Study Group for Pancreatic Cancer even evidenced 
potential deleterious effects for chemo radiotherapy versus chemotherapy [42]. 
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Neoadjuvant therapy 
As much as 26% of patients with a tumor considered as resectable suffer from metastatic evo-
lution 3 months after surgery [43]. In this context, the rationale for proposing preoperative chemo 
radiation regimens in potentially resectable pancreatic cancer is three-fold [44]: first, neoadjuvant 
treatment would eliminate the delay of adjuvant treatment due to postoperative recovery; second, 
neoadjuvant treatment might downstage tumors, thus increasing the likelihood of negative surgi-
cal margins; and third, neoadjuvant treatment could help prevent peritoneal tumor cell implanta-
tion and dissemination caused by manipulation during surgery. Preoperative chemo radiation for 
pancreatic cancer was pioneered by Evans et al. in a phase II trial administering preoperative 
radiation (50.4 Gy) and concurrent continuous infusion 5-FU 300 mg/m2/day in 28 patients with 
cytological or histological proof of pancreatic head adenocarcinoma [45]. The ECOG then con-
ducted a trial testing preoperative continuous 5-FU 1000 mg/m2/day on days 2 to 5 and 29 to 32 
and mitomycin-C 10 mg/m2 on day 2 of a 50.4 Gy radiation schedule [46]. Of 53 patients, 41 
underwent surgery; 17 did not benefit from resection because of local extension or metastases, 
while 24 underwent resection and showed a median survival time of 15.7 months compared with 
9.7 for the entire group. 
More controversial is the ultimate role of downstaging neoadjuvant chemo radiation followed 
by surgery for patients with initially unresectable tumors. Indeed, interpretation of the literature is 
complicated by differences in respectability criteria. Moreover, it is argued that surgical compli-
cations may occur more frequently secondary to inflammation and fibrosis following chemo 
radiation [44]. 
LOCALLY ADVANCED AND METASTATIC PANCREATIC CANCER 
Being the main focus of the present report, this section will be further developed with a review 
of the use of recent chemotherapy modalities in this largely predominant subgroup of pancreatic 
cancer patients. General considerations about their management are however introduced first. 
Advanced pancreatic carcinoma is a major challenge to oncologists because of its chemo 
resistance. However, observation has long suggested that chemotherapy could improve survival 
time in inoperable pancreatic carcinoma [47, 48]. Especially the first trial, by Mallinson et al., led 
clinicians to test many chemotherapeutic drugs as single agents or in combination therapies in 
advanced pancreatic tumors. Response rates were highly variable and often not reproducible. 
Among chemotherapeutic agents, 5-fluorouracil (5-FU) has certainly been the most studied. 
Observed response rates were variable and did not show any consistent benefit on either survival 
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time or symptoms relief. Despite this lack of evidence in advanced pancreatic carcinoma man-
agement, 5-FU was the first chemotherapeutic agent considered as the treatment of choice for this 
affection, since other molecules or combinations had failed to demonstrate any improvement in 
response rates or survival time. Over the last decade however, gemcitabine, a pyrimidine antime-
tabolite, was shown to somewhat improve disease stabilization, clinical benefit response and sur-
vival time. After approval for use in the late 1990s, this agent is now considered as first choice 
for treatment of advanced pancreatic cancer. These observations tended to boost clinical research 
on combinations with other chemotherapeutic agents as well as radiation therapy. It is obvious 
now that the introduction of gemcitabine did not fundamentally change the prognosis of advanced 
pancreatic cancer in terms of classical endpoints such as survival time, and that its quantitative 
benefit is only minor. However, before the approval of gemcitabine in this indication, chemother-
apy was considered as not very efficient and was therefore not systematically offered to patients. 
Pioneer studies with gemcitabine, demonstrating significant benefits in terms of symptoms 
improvements, changed the attitude of oncologists, as reflected by the exponential increase in the 
literature about palliative management of advanced pancreatic cancer over the last decade. Che-
motherapy is now considered as an important therapeutic modality in this management, and an 
intense clinical research activity is underway to determine the most efficient regimen. 
In addition to chemotherapy, palliation by surgical or medical means is of primary importance: 
when advanced disease is diagnosed. For example, biliary bypass may be indicated in patients 
with obstructive jaundice, and duodenal bypass when gastric outlet obstruction is pending. For 
the numerous patients whose predominant symptom is pain, use of long-acting opiate analgesics 
may be indicated. When ineffective or not tolerated, intra operative, percutaneous or EUS-
directed celiac block may provide adequate and efficient pain relief [49]. Also, to compensate for 
pancreatic exocrine failure, patients can be supplemented with enteric-coated pancreatic enzymes. 
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CHEMOTHERAPY IN ADVANCED PANCREATIC CARCINOMA:  
LITERATURE REVIEW 
This section systematically reviews the results of recently published studies regarding man-
agement of advanced pancreatic carcinoma. The respective references were obtained on Medline 
or by consulting review articles [50-58]. General considerations about clinical endpoints are pre-
sented first. 
METHODOLOGICAL CONSIDERATIONS 
PERFORMANCE STATUS 
The Karnofsky index [59] rates performance on a 0 to 100 scale in steps of 10 depending on 
patient’s ability to perform normal activities and to do active work as well as on need for 
assistance: 
- 100: Normal, no complaints, no evidence of disease 
- 90:  Able to carry on normal activities, minor signs of symptoms of disease 
- 80:  Normal activity with effort, some signs or symptoms of disease 
- 70:  Cares for self, unable to carry on normal activity or to do active work 
- 60:  Requires occasional assistance, but able to care for most of his needs 
- 50:  Requires considerable assistance and frequent medical care 
- 40:  Disabled, requires special care and assistance 
- 30:  Severely disabled, hospitalization indicated though death not imminent 
- 20:  Very sick, hospitalization necessary, active supportive treatment necessary 
- 10:  Moribund, fatal processes progressing rapidly 
- 0:  Dead 
An alternate categorization of performance status was then developed by the ECOG [60], pro-
viding a five-point scale easier to use and more precise and narrow in its message: 
- 0: Normal activity 
- 1: Symptoms, but nearly ambulatory 
- 2: Some bed time, but needs to be in bed less than 50% of normal daytime 
- 3: Needs to be in bed more than 50% of normal daytime 
- 4: Unable to get out of bed 
Intra- and inter observer correlations for the two scales were found to be very high [61] and 
some authors even developed an equivalency table between them [62]. 
EVALUATION OF RESPONSE IN PANCREATIC CANCER 
Response to chemotherapy is highly dependent on performance status and disease stage at ini-
tial diagnosis [63]. Thus, comparison between studies is difficult due to the variability in such 
prognostic factors at the time of inclusion. Moreover, despite modern imaging techniques, it is 
frequently impossible to get accurate localization and measurement of tumor extension within 
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adjacent tissues because of the desmoplastic and local inflammatory reactions induced by the dis-
ease itself, making it particularly difficult to differentiate between tumor and normal surrounding 
tissue [64]. Consequently, tumor response may be underestimated because reactive tissue would 
not readily shrink during successful chemotherapy, or by contrast overestimated in case of faster 
decrease of inflammatory reactions. Endoscopic ultrasound has been shown to be more sensitive 
than CT scan for the assessment of the initial tumor and regional lymph nodes (i.e. staging), but 
its performance is not better when it comes to the follow-up assessment of pancreatic parenchyma 
[65, 66], a situation that might change with recent developments in three-dimensional linear 
endoscopic ultrasound [67]. Hence, clinicians are facing two problems of tumor size definition at 
the time of diagnosis and of imprecise estimation of tumor response after chemotherapy. There-
fore, conventional endpoints such as tumor response rates may well inadequately evaluate 
response to treatment [64]. Unfortunately, the vast majority of studies considered stabilization of 
disease as the primary goal of palliative treatment and focused on such outcomes as complete 
response (disappearance of all known disease), partial response (50% or more decrease in tumor 
size) and stable disease (between 50% decrease and 25% increase in tumor size), according to the 
reduction, stabilization or increase of the primary tumor and/or its metastases as evidenced by 
radiological findings (World Health Organization reporting principles for results of cancer treat-
ment [68]). From that perspective, it might be worth paying more attention to survival data, 
namely median survival time and 1-year survival probability, the latter characterizing patients 
who showed a prolonged treatment benefit and providing superior information about the 
responder minority. 
Importantly, specific attention was given in recent years to pain relief and improvement of 
other disease-related symptoms, leading to the development of the Clinical Benefit Response 
(CBR) notion. CBR is a measure of clinical improvement in terms of pain intensity and analgesic 
consumption, performance status and weight change: a patient is considered as a responder if 
rated positive for either of the primary measures of pain (i.e. reduction of more than 50% in pain 
intensity or analgesics consumption) or performance status (i.e. improvement of KPS by more 
than 20 points) for at least 4 weeks without a negative rating in the other parameters within 12 
weeks, or if there is a weight gain of 7% above pretreatment baseline while the two primary 
parameters remain stable [69]. CBR is now considered as a better indicator of therapeutic 
efficacy in palliative settings in pancreatic cancer, as clinical experience has shown that small 
reductions of tumor size, corresponding to stable disease from radiological criteria, may often 
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lead to spectacular improvements of pain and abdominal discomfort symptoms. Indeed, because 
of its proximity to the celiac ganglion and its propensity for early invasion of this structure, small 
changes in size of a pancreatic adenocarcinoma can lead to significant relief of symptoms. Evi-
dence of the impact of gemcitabine on CBR is the main rationale, which supports its current 
position as a first-choice treatment modality in advanced pancreatic cancer. 
Regarding serum markers, the prognostic importance of CA 19-9 has been demonstrated for 
adjuvant treatment of operable pancreatic cancer [70]. Stemmler et al. [71] evaluated patients 
with advanced pancreatic carcinoma and initially elevated CA 19-9 levels, who were subse-
quently treated with a gemcitabine-cisplatin combination regimen. Interestingly, independent of 
CT response evaluation, CA 19-9 responders survived significantly longer than CA 19-9 non-
responders (9.8 versus 5.8 months, P=0.022), suggesting that CA 19-9 serum kinetics may serve 
as an early and reliable indicator of response and warranting further evaluation. 
In the future, Positron Emission Tomography (PET) may be more sensitive than traditional 
imaging as a technique to measure treatment response in pancreatic cancer [50]. Indeed, uptake 
and phosphorylation of glucose is higher in tumor cells, making it possible to tell apart malignant 
and nonmalignant tissue in the tumoral region. 
5-FLUOROURACIL 
Although many oncologists considered the thymidylate synthase inhibitor 5-FU as a standard 
treatment prior to the introduction of gemcitabine, there was no consistent evidence to support its 
benefit in patients with advanced pancreatic cancer in terms of disease response, survival time or 
quality of life. Indeed, drug efficacy (bolus 5-FU alone or biomodulated by folinic acid or inter-
feron) measured by objective response rate was highly variable, as well as median survival time, 
reported to range between 3.5 and 6.2 months in a recent review [55]. However, recent assess-
ment of high dose 24-hour infusion 5-FU 2600 mg/m2 and of capecitabine 2500 mg/m2 (oral 
equivalent to 5-FU, which simulates a continuous infusion) showed median survival times of 8.3 
months and 6.1 months, respectively, with low toxicity, suggesting some efficacy of 5-FU 
administered intravenously at continuous high doses [72, 73]. 
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OTHER SINGLE-AGENT MODALITIES [55] 
Topoisomerase I inhibitors: Irinotecan (or CPT-11) was associated with response rates of 9% 
and a median survival time of 5.2 months [74]. Rubitecan or 9NC showed activity in previously 
untreated patients with a median survival time of 7.3 months [75]. Exatecan showed an encourag-
ing activity with a median survival time of 10.6 months, and warrants further clinical evaluation 
alone or in combination. Myelosuppression is the principal side effect of these drugs. 
Taxanes: Both docetaxel (Taxotere®) and paclitaxel showed very modest activity in advanced 
pancreatic cancer with low response rates and a median survival time of approximately 5 months 
[76-79]. Jaundice and liver dysfunction is a clear limit in treatment with taxanes. 
Platins: Cisplatin and oxaliplatin used alone are only modestly active, with published median 
survival times of 3.4 to 4 months and response rates of 21% [80]. Combination with 5-FU yields 
better results, with a median survival time between 4 and 11 months according to the regimen. 
GEMCITABINE 
INITIAL PHASE I-II SINGLE-AGENT STUDIES 
Several initial phase I-II studies established gemcitabine as a promising molecule in the che-
motherapy of advanced pancreatic cancer, encouraging its subsequent evaluation in methodologi-
cally more robust trials. These protocols used 800-1500mg/m2 of gemcitabine on a weekly basis, 
in either the conventional 4-week schedule (treatment on days 1, 8 and 15) or the initial 7-week 
regimen (treatment continuously for 7 weeks with one week of rest, followed by the regular 4-
week schedule). Table 1 at the end of this section summarizes the details of these studies. 
Although observed objective response rates were relatively low (4.3% to 18.2%), there were a 
substantial number of patients who exhibited stable disease (18.8% to 50%). Excluding the trial 
of Rothenberg et al. [81], which enrolled patients who were experiencing disease progression 
under 5-FU therapy, the median overall survival time was 4.8 to 9.8 months, i.e. higher than the 
typical 3-6 months survival time without treatment. 1-year survival ranged between 14.3% and 
39%. Importantly, CBR was achieved in 26.6% to 48% of the patients, and toxicities were gener-
ally mild and manageable, with grade 3-4 mostly reversible hematological toxicities ranging from 
6.1% to 27.3% (leucopenia), 6.6% to 36.4% (neutropenia), 0% to 18% (thrombocytopenia) and 
3% to 22% (anemia). Other toxicities were mild, with nausea and vomiting, fever, rash and 
transaminase elevation most commonly reported. 
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Following these encouraging results, other administration modalities of gemcitabine were 
evaluated, for instance a high-dose infusion (2200 mg/m2) [82] and a fixed dose-rate infusion 
regimen (10 mg/min/m2) [83]. These alternatives to the conventional gemcitabine administration 
modalities are still undergoing clinical validation and are not considered as standard yet. 
PHASE III SINGLE-AGENT STUDIES 
Subsequently, single-agent gemcitabine regimens were evaluated in randomized phase III trials, 
six of which are detailed in Table 2 at the end of this section, as reviewed by Fung et al. [51]. 
The pioneer trial by Burris et al. [84] demonstrated superiority of gemcitabine over 5-FU as a 
first-line therapy in patients with locally advanced or metastatic pancreatic carcinoma: 23.8% of 
patients in the gemcitabine arm achieved CBR compared to 4.8% in the 5-FU arm (P=0.002). 
Median survival time was 5.65 months versus 4.41 (P=0.003), and 1-year survival probability 
18% versus 2%. The rather low values for median survival time have to be considered in the 
context of unfavorable eligibility criteria. 
Several other randomized trials later compared gemcitabine to newer therapeutic classes in 
pancreatic cancer treatment: the matrix metallo proteinase inhibitor marimastat [85] and Bay 12-
9566 [86]; ZD9331, a novel antifolate inhibitor of thymidylate synthase [87]; more recently the 
farnesyl transferase inhibitor tipifarnib [88]; and exatecan [89]. Single-agent gemcitabine 
systematically demonstrated its superiority to the other molecules. 
ASSOCIATION REGIMENS 
Considering that bi-therapies are often more effective than single-agent regimens in oncology, 
gemcitabine was also evaluated in combination with other chemotherapeutic molecules: 
• Gemcitabine and 5-FU 
After in vitro demonstration of synergistic cytotoxicity [90] and encouraging initial evaluation 
in phase I-II trials [91, 92] (reviewed by Oettle et al. [93]), a randomized phase III study by the 
ECOG recently failed to show any significant advantage of regimens combining gemcitabine and 
5-FU over gemcitabine alone [94, 95]. 
• Gemcitabine and cisplatin 
After in vitro observation of synergy in several other solid tumors [96] and encouraging early-
phase trials [97, 98], a recent randomized phase III study failed to show any significant difference 
in terms of survival time between gemcitabine alone and in combination with cisplatin [99], how-
ever being of small statistical power (97 patients). 
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• Gemcitabine and oxaliplatin (GemOx regimen) 
After in vitro observation of a sequence-dependent synergy with gemcitabine [100] and 
encouraging initial clinical trials [101, 102], a recent GERCOR/GISCAD study presented at the 
2004 ASCO meeting failed to reach statistical significance for the GemOx arm in comparison to 
single-agent gemcitabine in terms of overall survival time [103]. However, the GemOx arm evi-
denced significantly better response rate, clinical benefit and progression-free survival time, thus 
warranting further evaluation in trials designed with a higher statistical power. 
• Gemcitabine and irinotecan (IrinoGem regimen) 
Early-phase evaluation of this regimen evidenced only poor results [104, 105]. 
• Gemcitabine and docetaxel 
Early-phase evaluation of this regimen evidenced only poor results [106-110]. 
• Gemcitabine and epirubicin 
Early-phase evaluation of this regimen evidenced only poor results [111, 112]. 
During the last annual meeting of the American Society of Clinical Oncology, disappointing 
results were also presented for gemcitabine in combination with exatecan [113] or pemetrexed 
[114]. Hence, none of the above-mentioned association regimens demonstrated its superior-
ity to single-agent gemcitabine in terms of overall survival time so far. The results of two 
randomized phase III trials enrolling more than 300 patients and evaluating gemcitabine in com-
bination with capecitabine versus gemcitabine alone are expected in the early future (SAKK and 
MRC protocols). 
GEMCITABINE IN RADIO-CHEMOTHERAPEUTIC MODALITIES 
Gemcitabine demonstrated very potent radio sensitizing properties in preclinical studies [115, 
116], and radiation enhancement is achieved by using much lower doses than those resulting in 
cell kill. Gemcitabine-mediated radio sensitization is probably related to a concurrent disruption 
of deoxynucleotide pools (inducing an inhibition of radio-induced DNA damage repair) and a 
subsequent redistribution of cells into the radiosensitive S phase of the cell cycle [117, 118]. A 
few disparate trials have been reported, with varying objectives from palliative to curative, 
neoadjuvant or adjuvant use [51]. Among the variety of regimens that were evaluated, response 
rates varied from 16.7% to 57.1%, while toxicities were generally manageable with appropriately 
adapted doses of gemcitabine. 
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Several other trials evaluated more aggressive association regimens with radiation, for exam-
ple gemcitabine and 5-FU in protracted intravenous infusion [119, 120], gemcitabine and cis-
platin or gemcitabine and paclitaxel [121, 122]. Given the contrasting efficacy results of those 
early-phase trials, larger phase III studies will be necessary to determine the precise role of 
chemo radiation therapy in patients with locally advanced pancreatic cancer. 
SUMMARY 
Overall, these data show that the introduction of gemcitabine has only moderately benefited 
patients in terms of survival time, but much more significantly in terms of CBR. Although 
numerous combination regimens have undergone clinical testing, none has demonstrated its supe-
riority to gemcitabine alone in any randomized phase III study so far. Available evidence indi-
cates that remission rates of 10% to 30%, CBR of 40% to 60%, overall survival times of 7 to 10 
months and 1-year survival probabilities of 20% to 30% may be currently expected from chemo-
therapy in advanced pancreatic carcinoma with regimens based on single-agent gemcitabine [53]. 
This chemotherapeutic modality should currently be considered as the standard treatment outside 
any experimental protocol, until future randomized phase III trials establish the superiority of 
another drug or combination regimen. 
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Table 1 – Single-agent studies of gemcitabine in advanced pancreatic cancer 
Toxicity 
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Karasek 2003 [123] 
Prospective 
(observational) 
100 1000 x q3 of 4 13 48 61 26 NA 3.2 7.5 NA 8 3 5 G3/4 not observed 
Crino 2001 [124] Prospective (II) 33 1000 x 7 wk, then q3 of 4 wk 12.1 45.5 57.6 NA NA NA 7.7 9 NA 12 
12 
(G2/G
3) 
Nausea/vomiting G1/2 (24%/9%); G1/2 skin rash (9%); 
Peripheral edema (24%); Asthenia (39%); G1 alopecia 
(3%) 
Meyer 2001 [125] Prospective (II) 28 1000 x 7 wk, then q3 of 4 wk 7.2 39.2 46.4 NA 14.3 NA 9.8 11 NA 18 8 
G3: Diarrhea (7%); Nausea (7%); Edema (4%); Alopecia 
(20%) 
Okada 2001 [126] Prospective (I) 11 
(a) 1000 x q3 of 4 wk 
(b) 1000 x 7 wk, then q3 of 4 
wk 
18.2 36.4 54.6 28.6 18.2 NA 6.4 27.3 36.4 0 9.1 
G3/4 anorexia (27.3%); G3: Nausea/vomiting (9.1%); 
Fatigue (18.2%); GOT/GPT (9.1%); Weight loss (9.1%) 
Aykan 2000 [127] Prospective (II) 14 1000 x 7 wk, then q3 of 4 wk 14.3 50 64.3 NA 14.3 6 6 NA NA NA NA No G3/4 toxicity 
Kurtz 1999 [128] 
Prospective 
(compassionate) 
74 1000 x 7 wk, then q3 of 4 wk 4.3 39.1 43.4 48 NA NA 5 NA 27 14 22 
G3/4: Asthenia (11.6%); Nausea/vomiting (9.3%); 
Anorexia (7%); (Partial) occlusion (7%); Edema (2.3%); 
Cardiac insufficiency (2.3%); Embolization of catheter 
(2.3%); Arterial hypotension (2.3%); Jaundice (2.3%); 
Dehydration (2.3%); Abdominal pain (2.3%) 
Storniolo 1999 [63] 
Prospective 
(Investigational 
New Drug) 
3023 1000 x 7 wk, then q3 of 4 wk 10.6   18.4 15 2.7 4.8 NA NA NA NA 
Fever (7.3%); Pain (6.8&); Asthenia (6%); Abdominal 
pain (5.5%); Dyspnea (5%); Dehydration (4.5%); 
Nausea/vomiting (3.9%); Anorexia (3.6%); Deep 
thrombophlebitis (3.2%); Jaundice (3.2%); Ascites 
(2.9%); Edema (2.9%); Sepsis (2.4%) 
Manzano 1998 
[129] 
Prospective (II) 15 1000 x 7 wk, then q3 of 4 wk NA NA NA 26.6 39 NA NA NA 6.6 NA NA G4 asthenia (6.6%) 
Petrovic 1998 [130] Prospective (II) 11 1000 x 7 wk, then q3 of 4 wk NA NA NA 33 26 NA 6.65 NA NA NA NA Well tolerated 
Carmichael 1996 
[131] 
Prospective (II) 34 800 x q3 of 4 wk (max 1000) 6.3 18.8 25.1 NA NA NA 6.3 6.1 24.5 9.1 3 
G3: Nausea/vomiting (26.7%); Diarrhea (3.3%); Pain 
(3.3%); Consciousness alteration (3.3%) 
G2: Cutaneous (10%); Fever (20%); Infection (6.7%); 
Nausea/vomiting (20%); Consciousness alteration 
(13.3%) 
Rothenberg 1996 
[81] 
Prospective (II) 74 
1000 x 7 wk, then q3 of 4 wk 
(max 1250) 
10.5 29.8 40.3 27 4 2.53 3.85 9.8 26.2 4.9 11.4 
G4: Hemorrhage (1.6%); Vomiting (1.6%) 
G2/3: Constipation (4.8%/1.6%); Cutaneous (9.5%/0%); 
Fever (14.3%/1.6%); Alopecia (1.6%/0%); Infection 
(0%/3.2%); Nausea/vomiting (28.6%/6.3%); Oral 
mucositis (1.6%/0%); Pain (3.2%/1.6%); Peripheral 
neuropathy (1.6%/0%); Pulmonary (1.6%/0%); 
Consciousness alteration (1.6%/3.2%) 
Casper 1994 [132] Prospective (II) 44 800 x q3 of 4 wk (max 1500) 11 31.8 42.8 NA 23 3.7 5.6 NA NA NA NA 
Mild to moderate flu-like syndrome: 100% 
Mild hemolytic-uremic syndrome: 1pt 
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Table 2 – Randomized gemcitabine studies in advanced pancreatic cancer (underlined results correspond to a statistically significant difference between arms) 
Toxicity 
Hematological (G3/4) (%)  
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139 
Gemcitabine 1000 x 7 wk, then q3 of 4 
wk 
4.3 44.6 48.9 NA 25 3.5 6.6 NA 34.5 6.5 10.1 G3/4: Nausea (3.6%); Vomiting (5%); Lethargy (5.8%) 
Moore 2003 
[86] 
Randomized 
(III) 
138 Bay-12-9566 800 mg p.o. b.i.d. 0.7 22.5 23.2 NA 10 1.7 3.7 NA 2.2 0 10.1 G3/4: Nausea (8%); Vomiting (2.9%); Lethargy (6.5%) 
163 Gemcitabine 1000 x q3 of 4 wk 5.6 NA NA NA NA 2.2 5.4 16 5 11 10 G3/4: Diarrhea (4%); Nausea/vomiting (19%) 
Gemcitabine 1000 x q3 of 4 wk 
Berlin 2002 
[95] 
Randomized 
(III) 
164 
+ 5-FU 600 x q3 of 4 wk 
6.9 NA NA NA NA 3.4 6.7 29 7 19 10 G3/4: Diarrhea (10%); Nausea/vomiting (15%) 
44 
Gemcitabine 1000 x 7 wk, then q3 of 4 
wk 
9.2 33.4 42.6 49 NA 1.9 4.7 4 5 2 4 
G3/4: Mucositis (2%); Diarrhea (0%); Nausea/vomiting 
(2%) 
Gemcitabine 1000 x 7 wk, then q3 of 4 
wk 
Colucci 
2002 [99] 
Randomized 
(III) 
53 
+ Cisplatin 25 day 1 1h before gem. 
26.4 30.2 56.6 52.6 NA 4.7 7 4 9 2 6 
G3/4: Mucositis (0%); Diarrhea (4%); Nausea/vomiting 
(2%) 
103 
Gemcitabine 1000 x 7 wk, then q3 of 4 
wk 
26 NA NA NA 19 3.8 5.6 2 7 5 2 
G3/4: Cardiac dysfunction (1%); Constipation (1%); 
Fever without infection (1%); Infection (2%); Local 
(1%); Nausea (4%); Cortical (5%); Motor (4%); 
Pulmonary (9%); Skin (3%) 
104 Marimastat 5 mg b.i.d. 2.8 NA NA NA 14 1.8 3.7 0 1 3 4 
G3/4: Cardiac dysrhythmias (1%); Diarrhea (1%); 
Musculoskeletal (7%); Nausea (2%); Cerebellar (2%); 
Vision (1%); pulmonary (3%); weight gain or loss (1%) 
105 Marimastat 10 mg b.i.d. 2.8 NA NA NA 14 2 3.5 0 0 0 3 
G3/4: Musculoskeletal (7%); Nausea (1%); Motor (1%); 
Vomiting (1%) 
Bramhall 
2001 [85] 
Randomized 
(III) 
102 Marimastat 25 mg b.i.d. 2.8 NA NA NA 20 1.9 4.2 0 0 2 2 
G3/4: Musculoskeletal (12%); Nausea (1%); Motor 
(1%); Pulmonary (1%) 
54 Gemcitabine 1000 x q3 of 4 wk NA NA NA NA NA NA NA 5.5 NA 7.4 9.2 
G3/4: Mucositis (3.7%); Diarrhea (7.4%) 
G3: Nausea/vomiting (3.7%) 
Gemcitabine 1000 x q3 of 4 wk 
Heinemann 
2001 [133] 
Randomized 
(III) 
46 
+ Cisplatin 50 (day 1, 15) q4 wk 
NA NA NA NA NA NA NA 13 NA 8.6 13 
G3/4: Mucositis (4.3%); Diarrhea (10.8%) 
G3: Nausea/vomiting (33%) 
63 
Gemcitabine 1000 x 7 wk, then q3 of 4 
wk (max 1250) 
5.4 39 44.4 23.8 18 2.1 5.65 9.7 25.9 9.7 9.7 
G3/4: Nausea/vomiting (12-7%) 
G3: Diarrhea (1.6%); constipation (3.2%); consciousness 
alteration (1.6%); Pain (1.6%) 
Burris 1997 
[84] 
Randomized 
(III) 
63 5-FU 600 weekly 0 19 19 4.8 2 0.9 4.41 1.6 4.9 1.6 0 
G3: Nausea/vomiting (4.8%); Diarrhea (4.8%); 
Constipation (1.6%); Consciousness alteration (1.6%) 
 
 - 29 - 
RETROSPECTIVE STUDY ON A GENEVA COHORT 
INTRODUCTION 
Although not having revolutionarily improved classical therapeutic outcomes such as overall 
survival time in patients suffering from advanced pancreatic cancer, gemcitabine significantly 
improved more qualitative outcomes such as clinical benefit response, which is often physicians’ 
predominant concern in a palliative context. In parallel, it also markedly stimulated clinical 
research. 
Numerous combination regimens based on gemcitabine have been evaluated so far in early 
clinical trials, and promising ones are now undergoing further assessment in randomized phase III 
studies. However, for obvious methodological reasons, the experimental situation of those trials 
is often rather different from daily clinical practice, both in terms of patient homogeneity and of 
therapeutic algorithm rigidity. Therefore, and because introduction of gemcitabine in the mid-90s 
was a cornerstone in chemotherapeutic management of advanced pancreatic cancer, it seemed to 
us interesting to retrospectively analyze a Geneva cohort of patients suffering from this 
malignancy who were followed in the cantonal hospital over the last decade, considering out-
comes such as overall survival time and 1-year survival probability. Our baseline hypothesis was 
that the more organized and systematic delivery of chemotherapy after the above-mentioned 
introduction of gemcitabine would have improved those outcomes in comparison to the pre-
ceding period, when chemotherapy prescription for advanced pancreatic cancer was poorly stan-
dardized. Besides, other efficient medications for the management of advanced pancreatic cancer, 
such as oxaliplatin, were introduced following gemcitabine, and may also have contributed to 
further improve those outcomes (e.g., in second or third-line therapies). 
Economic concerns have a growing importance in healthcare-related discussions and decisions 
in most developed countries as the sector’s share of their gross national product is rising: 
clinicians are nowadays under increasing pressure to adopt more cost-effective treatment 
practices as a result of initiatives taken by major third-party payers, government and business. For 
example, in the Swiss hospital sector and following other European countries like Germany, there 
has recently been a movement towards adopting prospective payment systems based on 
diagnosis-related groups (DRGs) for the financial retribution of health care providers. 
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Although representing less than 1% of the population, physicians determine, through their 
decisions about their patients’ care, how nearly 10% of gross national product is being spent. 
Considerations of justice in macro allocation of scarce resources raise the question whether pro-
longing survival time by only a few months (e.g., in some oncology situations) can be considered 
as ethically justified with regard to society as a whole when incurred costs to achieve such results 
are enormously high. But because of methodological as well as practical hurdles, precise deter-
mination of incurred costs for a given diagnostic or therapeutic option in a given clinical setting 
has historically proven to be considerably difficult. Accordingly, cost-effectiveness and cost-
benefit studies are still rare in comparison to the wealth of publications considering clinical 
aspects of medicine. In particular, these studies were sometimes criticized for their low practical 
pertinence, given their often strongly rigorous experimental context. Therefore, it also seemed 
interesting to us to retrospectively conduct basic economical analyses in the same cohort of 
patients, i.e. mainly an assessment of costs. 
METHODOLOGY 
PATIENTS 
References of all patients eligible for this retrospective study were retrieved by data mining 
the local electronic Oncosurgery database in the Geneva Cantonal Hospital. All pancreatic ade-
nocarcinoma cases that were evaluated at least once by a practitioner belonging to this service 
from October 1st, 1993 to October 31st, 2003 were considered as being eligible. The final cohort 
was determined after exclusion of those patients who did not undergo at least one antitumoral 
therapy under the responsibility of the service, i.e. of all patients who were evaluated only and 
who underwent therapy outside of the cantonal hospital. 
DATA MINING 
First, we gathered epidemiological data from the Geneva Cancer Registry, which systemati-
cally records every cancer case among residents and non-residents, whether it be diagnosed in the 
public or the private setting, from hospital databases, state laboratories and independent practitio-
ner declarations as well as death certificates, among others. The total number of pancreatic carci-
nomas declared in the Geneva canton from 1993 to 2003 was thus determined, so as to appreciate 
the representativeness of the studied sample. 
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For each patient included in the study, the following information –when available– were then 
collected from paper and electronic medical records: 
- Sex; 
- Birth date; 
- Death date or censoring date; 
- Initial diagnosis date, defined so as to minimize as much as possible potential biases in 
survival time estimates and to allow for the maximal homogeneity of included patients: 
the date retained was the first day of the hospital stay leading to the diagnosis or its 
confirmation; 
- Known prognostic factors, including ECOG PS at the time of diagnosis, defined as the 
score mentioned in the record of the first oncosurgery consultation; tumor stage (TNM 
classification) at the time of diagnosis, re-interpreted according to the new 2002 classi-
fication system from initial radiological, surgical and pathological records; primary site 
at the time of diagnosis (head versus body and/or tail); and tumor size at the time of 
diagnosis, defined as the size in centimeters of the tumoral maximal axis mentioned on 
CT-Scan reports; 
- Treatment, including the first modality (curative surgery or chemotherapy), as well as 
subsequent radiotherapy and/or chemotherapy modalities. For chemotherapeutic proce-
dures, the number of effectively administered lines and cycles of each drug or drug 
association as well as the doses were collected; 
- Hospitalizations, including dates of entry and discharge, department and nature of stay 
(categorized as treatment, complication of treatment, complication of disease and 
others); 
- Economic data available from the hospital’s Medico-Economic Department and corre-
sponding to the costs for the institution of every hospitalization and ambulatory visit to 
the cantonal hospital for every included patient from the diagnosis of the disease to 
death or censoring (cf. further explanations about the detailed cost accounting proce-
dures of the Geneva Cantonal Hospital after the following section). 
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DATA ANALYSIS 
Group definition 
For each and every patient included, the following parameters were then calculated when the 
underlying information was available: 
- Age at diagnosis, calculated by subtracting the birth date from the retained diagnosis 
date; 
- Survival time, calculated by subtracting the retained diagnosis date from the death or 
censoring date. The date of October 31, 2003 was chosen as censoring date for patients 
still alive at the time of analysis. 
Then, two groups were defined on a chronological basis: patients included in the study were 
ranked according to the date of their initial diagnosis and their first-intent chemotherapeutic 
treatment was then considered (generally following diagnosis for stage III-IV patients and fol-
lowing recurrence for stage I-II resected patients), namely gemcitabine-containing regimen ver-
sus any other regimen. The diagnosis date for the first patient who received gemcitabine as a 
first-line therapy to manage his disease was used to distinguish between the two groups. Thus, 
group A comprised patients who did not receive gemcitabine as a first-line therapy, whereas all 
patients in group B received this drug first. In this process, we did not consider any chemotherapy 
regimen administered in combination with radiotherapy. We expected this date to occur some-
where in late 1998 according to the introduction of gemcitabine in Switzerland for this indication 
and its official reimbursement by health insurances. Although a few patients categorized in group 
A would inevitably prove to have received gemcitabine at some point of their later therapeutic 
management, by definition it was not as first-intent therapy. 
Following this step, statistic analyses for various parameters and outcomes were conducted. 
Chi-square tests were used for binomial comparisons (a Fisher’s exact test was employed when 
the number of patients under a given condition was inferior to five), as well as nonparametric 
Mann-Whitney tests for ordered numerical data such as age. Two-sided p-values were systemati-
cally calculated, and a level of 0.05 was considered as statistically significant for their interpreta-
tion. Concerning survival analyses as well as cost comparisons, graphs were constructed accord-
ing to the method developed by Kaplan and Meier [134], and log-rank tests were used to compare 
groups. SPSS 11.0 and GraphPad Prism 3 were used to compute those calculations. 
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Medical analyses 
The following analyses were conducted first: 
- Comparisons for demographic factors, mainly sex; 
- Comparisons for known prognostic factors, i.e. stage, tumor size and age at initial 
diagnosis; 
- Comparisons of treatment modalities and especially of the total number of chemother-
apy doses received. 
At this point, our first intention was to compare the two groups in terms of total survival time 
(i.e. from initial diagnosis to death or censoring), including patients diagnosed at early stages and 
resected as well as patients diagnosed at later stages and directly treated in a palliative setting. 
However, as will be presented in the results section, it turned out that groups A and B were sig-
nificantly inhomogeneous with respect to the proportion of stage I-II versus stage III-IV patients, 
group A including significantly more early stages. Therefore, any global survival comparison 
would have been inevitably biased by this difference in favor of group A, since it is well known 
that resected patients have a longer survival time than patients diagnosed at later stages and have 
different tumor biology. A potential solution to this issue would have been to compute survival 
time in a palliative setting for resected patients, i.e. from the time of their recurrence. However, 
precise definition of the date of recurrence is problematic: since survival time is so short for 
patients suffering from advanced pancreatic cancer, it is crucial to be as systematic as possible in 
such a definition to avoid important biases and analyze meaningful data. Since there was no sys-
tematic and standardized follow-up algorithm for these patients after resection in terms of radio-
logical examinations and biologic analyses in Geneva during the considered period, retaining as 
the date of recurrence the date of a CT-Scan evidencing loco regional recurrence or metastases, 
the date of a serum CA 19-9 elevation or the date of a consultation whose record concludes to the 
recurrence would all have jeopardized our results, being far too imprecise. Therefore, we decided 
to restrict the main analyses to stage III-IV patients only, i.e. to patients initially diagnosed at 
advanced stages and directly treated in a palliative setting. From a clinical viewpoint, this restric-
tion makes much more sense in that we ended up comparing homogeneous populations, with 
diagnosis dates as precisely defined as could be in a retrospective design. For indicative purposes, 
demographic figures regarding the whole cohort will be provided in the results section. 
 - 34 - 
The following analyses were then conducted in the cohort restricted to stage III-IV patients: 
- Primary endpoint: survival analysis; 
- Secondary endpoints: comparison of the two groups in terms of hospitalization days, 
distinguishing hospitalizations for treatment (e.g. permanent venous access implanta-
tion, chemotherapy or radiotherapy), complications of treatment (e.g. post-chemother-
apy fever with or without infection, severe vomiting or other treatment toxicity), com-
plications of disease (e.g. obstructive jaundice or ileus requiring surgical or interven-
tional radiological derivation procedures, cholangitis episodes and ultimately terminal 
care and death) and other causes. The first hospitalization, leading to or confirming the 
diagnosis, as well as the subsequent convalescence, were systematically considered as 
treatment. Finally, total incurred economic costs for the hospital were compared using 
log-rank tests to account for censored patients. 
Economical analyses 
• Cost analysis system in Geneva Cantonal Hospital 
As far as economic analyses and cost comparisons are concerned, some explanations about the 
method employed for costs computations using the cost accounting system used in the Geneva 
Cantonal Hospital are detailed below. The fundamental problem in cost accounting is to link 
costs actually incurred to a given unit of measurement –generally a product or service–, such as a 
particular stay for a particular patient due to a particular pathology. This process, known as allo-
cation, is far more complex than it seems at first glance, since costs such as administrative, 
maintenance, electricity or research and teaching expenditures –also known as indirect costs– 
need to be allocated to each unit of output according to specific criteria since they are not directly 
attributable to any given particular product or service. Indeed, although less critical than the 
direct costs of medications, medical consultations or radiological procedures, for example, which 
can all be related quite easily to a particular service, those indirect costs are at least as important 
to consider when the true consumption of resources driven by a particular output are to be deter-
mined. Thus, the problem is to choose the least bad allocation method, knowing that it will 
inevitably be wrong. Actually, true costs can never be known, although every organization needs 
to understand as precisely as possible the mechanisms of consumption of resources used to 
deliver its products/services. The process in the Geneva Cantonal Hospital can be summarized as 
follows: 
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1. Financial data is processed to obtain information about true expenses incurred by the 
consumption of individual resources (e.g. salary costs, electricity expenses, medica-
tions etc.) during a particular period; 
2. Those expenses are then related to specific basic activities of the hospital to yield spe-
cific costs (e.g. the specific overall cost of radiological procedures or of medical care). 
This step involves building a kind of virtual hospital, whose structure corresponds to 
its basic activities; 
3. Direct costs are linked directly to each type of service provided, while indirect costs 
need to be allocated to different activities to yield a complete unitary cost for each 
service (e.g. laboratory services, radiological exams, nurse and medical care). The 
complete unitary cost includes all direct costs for the service provided (e.g. a medical 
consultation, a particular radiological investigation or medications) as well as a given 
proportion of all support services, whose costs are indirect (e.g. maintenance, research 
and teaching expenses, electricity etc.); 
4. From the previous step, detailed unitary costs for various units of output are computed, 
such as the cost of one hour of hospitalization, the cost of one ambulatory visit to a 
particular department or the cost of one unit of laboratory or radiological procedure. 
Some of those data (such as the cost of one hospitalization day in a particular depart-
ment) are used for benchmarking and financing purposes; 
5. More importantly for our discussion, the detailed costs for each particular case can be 
further inferred from the detailed services provided in each care situation (listed as a 
result of the coding process at the end of each stay for each patient) as well as from 
previously calculated unitary costs. For example, if a patient has undergone the 
implantation of a permanent venous access device as well as the administration of two 
cycles of chemotherapy during a given stay, those services can be linked to their corre-
sponding unitary costs to yield the total cost of the stay. 
• Conversion into standard units 
Our intention was to compare costs incurred for patients who were hospitalized at different 
periods in time, spanning a decade, which is considerable from an economic perspective. Costs 
incurred for one hour of medical consultation in 1995, for example, are in no way directly com-
parable to the costs incurred for the same service in 2003: this is partly due to general inflation, 
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but more importantly to increases in general health care costs over the last decade. To overcome 
this problem, a weighting factor was calculated to express each cost in 2002 units. 2002 was 
chosen because most of the data for 2003 were not yet available at the time of analysis. To com-
pute those multiplication factors, the average cost of one typical hospitalization day in a general 
care unit of the Geneva Cantonal Hospital was considered, in each year previous to 2002, with 
respect to this reference period and based on the same database available from the Medico-
Economic Department. The average cost was obtained by dividing the total expenses incurred for 
general care units by the total number of hospitalization days in the same units. Comparison to 
2002 yielded several weighting factors, by which every cost incurred previous to this reference 
year was multiplied to obtain standardized values. This approach was deemed reasonable, since 
most hospitalizations of patients suffering from a palliative-stage pancreatic cancer occur in 
general care units. 
• Extra-hospital costs 
Costs incurred during rehabilitation stays outside of the cantonal hospital, i.e. mainly conva-
lescence stays, as well as costs of terminal care stays, were also included in the analysis. Consid-
ering that every convalescence stay is more or less comparable to another, in that it rarely 
includes specific and expensive surgical or radiological procedures, but only basic clinical man-
agement, a typical cost was calculated for one day of hospitalization in a convalescence hospital 
whose financial statements and activity report were available for 2002 (Clinique Genevoise de 
Montana). This value was then extrapolated to stays in other hospitals after correction for the 
year with respect to 2002. Total estimated costs for each stay were calculated simply by multi-
plying this unitary per diem value by the length of the stay. 
Last, the majority of patients included were followed almost exclusively by the oncology 
service during most of their disease. Hence, it is unlikely that major expenses were incurred out-
side this consultation. Consequently, and due to obvious methodological issues, extra-hospital 
costs were not considered in our medico-economic analyses. 
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RESULTS 
EPIDEMIOLOGICAL DATA 
The following pathologic variants of pancreatic cancer were considered when retrieving 
information from the Geneva Cancer Registry (reference [135] was used until 1994 and reference 
[136] from 1995 to 2002): 
- Neoplasm, malignant 
- Carcinoma, NOS 
- Carcinoma, anaplastic type, NOS 
- Adenocarcinoma, NOS 
- Tubular adenocarcinoma 
- Papillary adenocarcinoma, NOS 
- Mucoepidermoid carcinoma 
- Cystadenocarcinoma, NOS 
- Mucinous adenocarcinoma 
- Mucin-producing adenocarcinoma 
- Infiltrating duct carcinoma 
- Acinar cell carcinoma 
- Adenosquamous carcinoma 
- No microscopic confirmation; clinically malignant tumor 
According to information available from the Registry, the incidence of pancreatic carcinoma 
in the canton of Geneva was 13.3/100,000 newly diagnosed cases per year by men and 
12.3/100,000 by women (standardized rates, Geneva population), or 12.7/100,000 by men and 
8.3/100,000 by women (standardized rates, European population) from 1993 to 2001. 529 cases 
of pancreatic carcinoma were diagnosed between January 1st, 1993 and December 31st, 2001 in 
the canton of Geneva (about 400’000 inhabitants). 462 cases were residents in the canton at the 
time of diagnosis and 67 cases were non-residents. Data for 2002 and 2003 were not available at 
the time of analysis. Among these 529 cases, 51.8% were classified as adenocarcinoma, not oth-
erwise specified, and 31.9% as clinically malignant tumors without microscopic confirmation. 
The breakdown by year is shown in the following table: 
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Year Residents Non-Residents 
1993 56 7 
1994 62 12 
1995 40 5 
1996 47 4 
1997 43 4 
1998 57 5 
1999 45 12 
2000 56 9 
2001 56 9 
Total 462 67 
Table 3: Number of pancreatic carcinoma cases diagnosed in Geneva from 1993 to 2001 
PATIENTS AND GROUPS 
Our research on the Oncosurgery database in the cantonal hospital yielded a total of 86 
patients who were followed by the service for a pancreatic adenocarcinoma during at least one 
treatment cycle following the diagnosis of their disease from October 1st, 1993 to October 31st, 
2003. Of these, two patients had to be excluded, one because his pancreatic tumor never recurred 
after initial curative-intent surgery (and we intended to consider treatment at a palliative stage), 
and one because his tumor was actually not of pancreatic origin, as evidenced by pathology 
reports (it was an ampulla of Vater carcinoma). Thus, the final cohort consisted of 84 patients, 
who were subsequently ranked according to the date of diagnosis. The pivotal date retained to 
distinguish between group A and B was December 22, 1998, corresponding approximately to the 
generalization of gemcitabine use in Switzerland (second half of 1998) in this indication. 
Accordingly, a Group A, consisting of 39 patients, and a Group B, consisting of 45 patients, 
were defined. The following table details the percentage of newly diagnosed cases of pancreatic 
carcinoma in Geneva followed in Oncosurgery in the cantonal hospital, and included in the pre-
sent study. 1993 was not included in the total percentage calculation, since the starting point for 
inclusion was only October of this year: 
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Year 
Number of cases diagnosed 
and followed-up in 
Oncosurgery 
Corresponding percentage 
of total diagnosed cases in 
Geneva 
1993 (October onwards) 1 2% 
1994 11 15% 
1995 6 13% 
1996 5 10% 
1997 7 15% 
1998 9 15% 
1999 8 14% 
2000 12 18% 
2001 16 25% 
2002 6 NA 
2003 2 NA 
Total (1994-2001) 74 16% 
Table 4: Percentage of pancreatic cancer patients diagnosed in Geneva and followed-up in Oncosurgery in 
the Cantonal Hospital 
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Demographic and prognostic characteristics of the two groups are shown below: 
Parameter Value Group A (n=39) Group B (n=45) Statistical Test p-value 
F 16 (41%) 15 (33%) 
Sex M 23 (59%) 30 (67%) 
Chi-Square 0.47 
I 3 (8%) - (0%) 
II 14 (36%) 9 (21%) 
III 7 (18%) 13 (30%) 
IV 15 (39%) 22 (50%) 
Stage at 
diagnosis 
Missing - 1 
Mann-Whitney 0.06 
Head 25 (68%) 29 (64%) 
Body/Tail 12 (32%) 16 (36%) Primary Site 
at diagnosis Missing 2 - 
Chi-Square 0.77 
Range 1.5-6 1.5-7 
Median 4 4 Tumor Size at 
diagnosis (cm) Missing 12 7 
Mann-Whitney 0.93 
Range 41-78 44-79 
Median 60 66 
25th 
Percentile 
50 60 
Age at 
diagnosis 
75th 
Percentile 
68 72 
Mann-Whitney 0.03 
0 10 (39%) 7 (27%) 
1 11 (42%) 13 (50%) 
2 5 (19%) 5 (19%) 
3 - (0%) 1 (4%) 
ECOG PS at 
diagnosis 
Missing 13 19 
Mann-Whitney 0.41 
Curative 
Surgery 
(Stages I-
II) 
17 (44%) 10 (22%) 
Initial 
Treatment Palliative 
(Stages 
III-IV) 
22 (56%) 35 (78%) 
Chi-Square 0.04 
Table 5: Patients characteristics 
As evidenced in Table 5, the two groups were roughly comparable in terms of demographic 
factors such as sex (p=0.47), but not in terms of prognostic factors: indeed, while primary site, 
tumor size and ECOG PS at initial diagnosis were quite homogeneous between the two popula-
tions (p=0.78, 0.93 and 0.41, respectively), age as well as stage at initial diagnosis differed sig-
nificantly (p=0.03 and 0.06, respectively, this latter result being at the significance limit). Ageing 
is usually considered as a general prognostic factor for oncologic diseases, in part according to 
the assumption that co morbidities generally increase with advancing age. Histogram graphs with 
a theoretical normal curve as well as box plots for age at diagnosis are reproduced below for the 
two groups: 
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Figure 1: Histogram graph for age at diagnosis (Group A) 
 
Figure 2: Histogram graph for age at diagnosis (Group B) 
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Figure 3: Box plot for age at diagnosis (total cohort) 
More importantly, and as mentioned in the methodology section, it appeared that the propor-
tion of patients diagnosed at early stages, when a curative first-intent therapy could still be 
offered (stages I and II), was higher in group A than in group B. Indeed, considering together 
stages I-II versus stages III-IV, proportions were respectively 44%/56% for group A versus 
22%/78% for group B (p=0.04). As evidenced in the preceding literature review, it is well known 
that patients who can be offered a curative-intent pancreatic resection have a longer survival time 
than those whose tumor is diagnosed at a palliative stage, and who can be offered chemothera-
peutic management only. Tumor biology, in terms of clinical evolution and response to treatment, 
is clearly different between the two situations. Thus, the two groups initially defined were not 
comparable because of this significant difference in proportions between early and late stages, 
which would have introduced a strong bias in favor of group A in subsequent global survival 
comparisons. Therefore, we excluded all patients who had benefited from a surgical resection, i.e. 
all patients who were diagnosed with a stage I or II tumor, and considered stage III-IV patients 
only, i.e. patients who were directly treated in a palliative setting. This exclusion yielded a 
smaller cohort, consisting of 22 patients for group A and 35 for group B. Subsequent analyses 
were conducted on this restricted cohort. Demographic and prognostic factors comparisons are 
presented below: 
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Parameter Value 
Group A 
(n=22) 
Group B 
(n=35) 
Statistical 
Test 
p-
value 
F 9 (41%) 12 (34%) 
Sex M 13 (59%) 23 (66%) 
Chi-Square 0.61 
III (locally advanced 
disease) 
7 (32%) 13 (37%) 
Stage at diagnosis IV (metastatic 
disease) 
15 (68%) 22 (63%) 
Chi-Square 0.68 
Head 11 (55%) 19 (54%) 
Body/Tail 9 (45%) 16 (46%) Primary Site at 
diagnosis Missing 2 - 
Chi-Square 0.96 
Range 2-6 1.5-7 
Median 4 4 Tumor Size at 
diagnosis (cm) Missing 9 6 
Mann-
Whitney 
0.65 
Range 41-78 50-79 
Median 59 66 
25th Percentile 50 61 Age at diagnosis 
75th Percentile 65 73 
Mann-
Whitney 
0.005 
0 6 (38%) 6 (30%) 
1 6 (38%) 9 (45%) 
2 4 (24%) 4 (20%) 
3 - 1 (5%) 
ECOG PS at 
diagnosis 
Missing 6 15 
Mann-
Whitney 
0.74 
Table 6: Patients characteristics (Stage III-IV at initial diagnosis) 
The two groups were still comparable for sex (p=0.61), primary site, tumor size and ECOG PS 
at initial diagnosis (p=0.96, 0.65 and 0.74, respectively). In contrast to the preceding comparison, 
the two populations were also comparable in terms of stage at diagnosis, with roughly two thirds 
of patients initially diagnosed with stage IV (i.e. metastatic) disease, and one third with stage III 
(i.e. locally advanced) disease (p=0.68). However, age at diagnosis was still inhomogeneous 
between the two populations (p=0.005), as illustrated by the following histograms with a theo-
retical normal curve as well as by the corresponding box plot: 
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Figure 4: Histogram graph for age at palliative diagnosis (Group A) 
 
Figure 5: Histogram graph for age at palliative diagnosis (Group B) 
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Figure 6: Box plot for age at palliative diagnosis (stage III-IV patients only) 
TREATMENT 
Details of the surgical, radio therapeutic and chemotherapeutic management for the two 
groups of patients are shown below. Figures for chemotherapeutic modalities represent the num-
ber of doses administered. For indicative purposes, data for the total cohort are also provided: 
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Total Cohort Stage III-IV patients 
Treatment Modality 
Group A (n=39) Group B (n=45) Group A (n=22) Group B (n=35) 
Curative-intent 
Duodenopancreatectomy 
15 10 - - 
Curative-intent left 
Splenopancreatectomy 
2 - - - 
Palliative-intent surgical 
intestinal derivation 
11 7 10 7 
Palliative-intent biliary 
derivation 
8 7 8 7 
Palliative-intent biliary 
stent 
3 9 3 9 
Palliative-intent 
intestinal stent 
- 1 - 1 
Adjuvant Chemo 
radiotherapy (45-60 Gy) 
14 (6 with 5-FU 500 
mg/m2 and 6 with 
Cisplatin 6 mg/m2) 
9 (7 with 5-FU 500 
mg/m2 and 2 with 
Cisplatin 6 mg/m2) 
- - 
Palliative-intent 
Radiotherapy (30-60 
Gy) 
8 10 8 10 
Gemcitabine 1000 
mg/m2 
11 (92 doses) 11 (107 doses) 6 (54 doses) 8 (71 doses) 
Gemcitabine 1000 
mg/m2 + Capecitabine 
1300 mg/m2 
2 (12 doses) 31 (350 doses) - 25 (331 doses) 
Oxaliplatin 50-80 mg/m2 
+ Irinotecan 50-80 
mg/m2 
2 (3 doses) 14 (56 doses) - 12 (52 doses) 
Leucovorin 30 mg/m2 + 
5-FU 2300 mg/m2/24h 
14 (206 doses) 13 (122 doses) 7 (28 doses) 12 (118 doses) 
Leucovorin 30 mg/m2 + 
5-FU 500 mg/m2 iv 
7 (93 doses) 1 (2 doses) 3 (14 doses) 1 (2 doses) 
5-FU 1700-2000 
mg/m2/wk 
1 (1 dose) 2 (17 doses) - 2 (17 doses) 
Docetaxel 25-30 mg/m2 
+ CPT-11 50-90 mg/m2 
1 (1 dose) 1 (6 doses) - 1 (6 doses) 
5-FU 200 mg/m2 + 
Cisplatin 60 mg/m2 + 
Epirubicin 50 mg/m2 
2 (4 doses) - 2 (4 doses) - 
Epirubicin 120 mg/m2 1 (2 doses) - 1 (2 doses) - 
Total number of 
effectively administered 
doses 
414 660 102 597 
Range of per-patient 
administered doses 
0-124 0-80 0-19 0-80 
Median per-patient 
administered doses 
2 11 1 14 
Log-rank p-value 0.07 0.0002 
Table 7: Treatment characteristics for the total cohort and for stage III-IV patients 
5-FU and Cisplatin doses given as part of a chemo radio therapeutic regimen are not mentioned under 
chemotherapeutic regimen, and were not included in total cycles calculations. 
Median number of total per-patient administered doses and p-value were computed using a log-rank test to 
account for censored patients 
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The following Kaplan-Meier graph illustrates the significant difference in per-patient admin-
istered doses for the two groups of stage III-IV patients: 
 
Figure 7: Kaplan-Meier graph of total per-patient chemotherapy doses for stage III-IV patients. Figures 
indicated in parentheses correspond to (total patients; censored). A tick indicates censored patients. 
Log-rank p=0.0002 
This graph provides the proportion of patients having received a given amount of chemother-
apy doses from initial diagnosis to death or censoring. 
SURVIVAL ANALYSES 
While none of stage III-IV patients included in group A was still alive and none had been cen-
sored, four stage III-IV patients included in group B were still alive and undergoing therapy at the 
time of analysis (October 31st, 2003). The total survival time Kaplan-Meier graph is shown 
below: 
 - 48 - 
 
Figure 8: Kaplan-Meier graph of palliative survival time for stage III-IV patients. Figures indicated in 
parentheses correspond to (total patients; censored). A tick indicates censored patients. 
Median survival time was 214 days for group A and 262 days for group B. 
Log-rank p=0.012. Hazard ratio=0.52 (95% CI=0.23 to 0.84) 
This graph plots survival time in palliative stage along the x-axis and the proportion of patients 
still alive at any point in time along the y-axis. 
Statistics Group A (n=22) Group B (n=35) 
Median Survival time 214 days (7.1 months) 262 days (8.7 months) 
95% confidence interval 131-296 days 116-408 days 
25
th
 Percentile 265 days (8.8 months) 785 days (26.2 months) 
75
th
 Percentile 107 days (3.6 months) 112 days (3.7 months) 
1-year Survival probability 14% 40% 
95% percentage confidence 
interval 
3-35% 24-58% 
Log-rank p-value 0.012 
Table 8: Log-rank test results for survival comparison in stage III-IV patients 
Thus, this analysis revealed a statistically significant difference in survival time between the 
two groups: median survival time was 7.1 months and 1-year survival probability was 14% for 
group A versus 8.7 months and 40% for group B, respectively (p=0.012, hazard ratio=0.52, 95% 
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CI 0.23-0.84). As evidenced by an increasing gap between the two curves after 300 days, patients 
having survived more than one year mainly accounted for this difference, i.e. group B long-term 
survivors survived significantly longer than group A ones. 
Building on the previously observed significant difference between the two groups in terms of 
total per-patient administered chemotherapy doses, this latter variable was plotted against 
survival time: 
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Figure 9: Total number of per-patient doses versus survival time graph for stage III-IV patients. 
Non-parametric Spearman’s correlation coefficient ρ=0.76 
As expected, the longer patients survived, the more doses of chemotherapy they received. 
Non-parametric analysis of this association yielded a Spearman’s correlation coefficient ρ of 
0.76. 
HOSPITALIZATION DAYS 
Four basic categories of hospitalization were distinguished: hospitalization for treatment pur-
poses, hospitalization due to treatment complications, disease complications, and finally other 
causes not related to treatment or disease. Detailed results corresponding to these categories are 
provided below, without consideration of patients group: 
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Treatment 
Treatment 
complications 
Disease 
complications 
Others 
Category 
Number of 
stays 
Category 
Number of 
stays 
Category 
Number of 
stays 
Category 
Number of 
stays 
Diagnosis 
51 (including 
10 explorative 
laparotomies) 
Fever 
following 
chemotherapy 
4 Terminal care 41 Unknown 11 
Port-a-Cath 
implantation 
38 
Treatment 
toxicity 
6 (including 1 
allergy, 1 
diarrhea, 2 
nausea & 
vomiting) 
Jaundice  
Biliary stent 
12 
Unrelated 
digestive 
hemorrhage 
1 
Digestive 
derivation 
16 
Port-a-Cath 
change 
2 Fever 
14 (including 
3 pneumonia) 
  
Biliary 
derivation 
8 Hypoglycemia 1 
General 
decline 
10   
Chemotherapy 9 
Anemia 
following 
anastomotic 
ulcer 
1 Ileus 
8 (including 6 
derivations) 
  
Convalescence 6   Thrombosis 
5 (including 2 
Trousseau’s 
syndromes) 
  
Radiotherapy 1   Ascites 3   
    Pain 3   
    Hernia 3   
    
Digestive 
hemorrhage 
3   
    
Bone 
metastasis 
2   
    
CNS vascular 
event 
2   
    Convalescence 2   
    
Inaugural 
diabetes 
2   
Table 9: Number of stays for different hospitalization categories 
Categories are not mutually exclusive, i.e. a single stay may have been justified by several categories. 
Derivative procedures were considered as treatment when occurring during the same stay as the diagnosis 
In terms of total hospitalization days, a log-rank test was conducted to account for censored 
patients. The corresponding Kaplan-Meier graph is shown below: 
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Figure 10: Kaplan-Meier graph of total days of hospitalization for stage III-IV patients. Figures indicated 
in parentheses correspond to (total patients; censored). A tick indicates censored patients. 
Log-rank p=0.50 
This graph indicates the proportion of patients having reached a particular number of hospi-
talization days from diagnosis to death or censoring. With a median of 55 days in group A and 60 
days in group B, the two populations were not significantly different (log-rank p=0.50). 
Considering this result and the significant difference in terms of total survival, it was thus 
expected that the ambulatory survival time (calculated as total survival time minus hospitalization 
days) be significantly different between the two groups. The corresponding Kaplan-Meier graph 
is shown below: 
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Figure 11: Kaplan-Meier graph of palliative ambulatory survival time (total survival minus hospitalization 
days) for stage III-IV patients. Figures indicated in parentheses correspond to (total patients; censored). A 
tick indicates censored patients. 
Median ambulatory survival time was 144 days for group A and 199 days for group B. 
Log-rank p=0.013. Hazard ratio=0.52 (95% CI=0.24 to 0.84) 
Indeed, the two groups were shown to differ significantly in terms of ambulatory survival 
time, with a median of 144 days for group A patients and 199 days for group B (p=0.013, hazard 
ratio=0.52, 95% CI 0.24-0.84). 
The two groups were then compared in terms of ambulatory visits to Oncosurgery in the can-
tonal hospital: assuming that patients who survived longer were also followed and treated for a 
longer period of time, one could expect a higher number of consultations for group B patients. 
The corresponding Kaplan-Meier graph is shown below: 
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Figure 12: Number of ambulatory visits in Oncosurgery for stage III-IV patients. Figures indicated in 
parentheses correspond to (total patients; censored). A tick indicates censored patients. 
Median=21 (Group A) and 28 (Group B). Log-rank p=0.007 
Thus, with a median of 28 visits, patients from group B were indeed seen significantly more in 
ambulatory consultations than patients from group A (median of 21 visits; p=0.007). 
ECONOMIC ANALYSES 
Cost data were not available for two Group B patients. Also, reliable economic information 
was only available from January 1st, 1995. Hence, all patients whose records showed a hospitali-
zation prior to this date were considered in economic analyses, which corresponds to 8 stage III-
IV patients in group A. Thus, economic analyses were finally conducted on 33 group B patients 
and 14 group A patients only. Remaining patients were handled as missing values in statistical 
tests. 
The following table shows the weighting factors that were computed to express all costs in 
2002-units: 
  
Year 
Weighting 
Factor 
  
  2003 1   
  2002 1   
  2001 1.0893   
  2000 1.1148   
  1999 1.0810   
  1998 1.1964   
  1997 1.1964   
  1996 1.1964   
  1995 1.1964   
Table 10: Weighting factors for costs conversion into 2002 units 
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A per diem cost for convalescence and terminal care stays was computed by dividing total 
expenses incurred by a clinic whose financial data were available (CHF 10,661,562.5) by its total 
hospitalization days over the corresponding period (23,700). This yielded an average per diem 
cost of CHF 449.85, which was rounded to CHF 450 to compute the costs of all convalescence or 
terminal care stays after conversion into 2002 units. 
Economic data for one patient is given below, as an example of the level of detail available: 
Table 11: Example of economic data for one patient 
Values in Swiss Francs (CHF), annualized to 2002 levels (cf. Methodology). 
Reference numbers censored for confidentiality purposes 
As evidenced in Table 11, it was possible to break down total costs into five subgroups of 
expenses, namely anesthesia, surgery, clinical care, imaging, laboratory and intensive care costs. 
The sum corresponds to the total in the fourth column. Medication costs were a further break-
down available; they are however already spread over the five above-mentioned categories. 
Finally, it was possible to distinguish between costs incurred for hospitalization stays and costs 
incurred for ambulatory visits to the hospital (i.e. mainly for chemotherapeutic treatment and 
follow-up in the context of the present analysis, since treatment was mainly provided on an out-
patient basis). Several visits are usually included under a unique reference number because of the 
hospital’s administrative process (i.e. the same reference number is used for every ambulatory 
visit until the patient is hospitalized). Similarly, convalescence and terminal care stays in other 
clinics were taken into account as explained by extrapolating a global cost from a theoretical per 
diem. 
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XXX XXX XXX XXX 30/01/2003 12,479       999        428        9,848      -      1,205     -     200     x
XXX XXX XXX XXX 13/02/2003 2,934          -        -        1,632      395     907        -     57       x
XXX XXX XXX XXX 13/03/2003 18,799       1,539     2,869     13,727    -      663        -     305     x
XXX XXX XXX XXX 23/04/2003 72               -        -        72           -      -        -     1         x
XXX XXX XXX XXX 10/05/2003 13,526       -        -        12,066    588     873        -     225     x
47,811     2,538   3,297   37,345   983   3,647   -    788   Total
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The following Kaplan-Meier graph shows total incurred costs for the two stage III-IV patients 
groups, i.e. the costs of all hospitalizations, all ambulatory visits to the cantonal hospital and all 
convalescence and terminal care stays for each patient: 
 
Figure 13: Kaplan-Meier graph of total costs incurred by the hospital for stage III-IV patients. Figures 
indicated in parentheses correspond to (total patients; censored). A tick indicates censored patients. Cost data 
were not available for 8 group A patients and 2 group B, who were treated as missing values. 
Monetary unit: CHF 
Log-rank p=0.76 
This graph provides the proportion of patients having reached a given cost from diagnosis to 
death or censoring. With a median of CHF 82,380 for group A and of CHF 76,750 for group B, 
the two populations were not significantly different (p=0.76) with respect to total costs incurred 
by the cantonal hospital, which include all care services provided both on an in-patient and out-
patient basis. 
Since the cost accounting system of the cantonal hospital allowed to distinguish between hos-
pitalization-related costs and costs related to ambulatory visits, statistics for the two categories 
were computed for indicative purposes using data available for deceased patients. Results are 
provided in the following table: 
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Subgroup A (n=14) Subgroup B (n=29) 
Statistic 
Cost 
Category Total 
patients 
Mean Median 
Total 
patients 
Mean Median 
Hospitalization 1,054,067 75,291 78,960 2,071,276 62,766 50,120 
Ambulatory 67,622 4,830 5,005 379,230 11,491 8,537 Total Costs 
Total 1,121,689 80,121 83,964 2,450,506 74,257 57,609 
Ratio Hosp:Amb  15.6:1 15.8:1  5.5:1 5.7:1 
Hospitalization 94%   85%   Proportion of 
total Ambulatory 6%   15%   
Hospitalization 
21,933 – 
168,873 
  
3,864 – 
173,732 
  
Range 
Ambulatory 
418 – 
11,513 
  
510 – 
42,877 
  
Table 12: Hospitalization-related and ambulatory costs for stage III-IV deceased patients 
Monetary unit: CHF 
Additional analyses were then conducted to further assess possible differences between the 
two groups along this dimension: given the absence of any significant difference in terms of hos-
pitalization days, one could expect that hospitalization-related costs would be comparable. How-
ever, considering that patients who survived longer were also followed and treated for a longer 
period of time, as evidenced by the number of ambulatory visits analysis, one could expect 
ambulatory costs in group B to exceed ambulatory costs in group A. Given the low proportion of 
total costs represented by ambulatory costs (approximately 6% in group A and 15% in group B), 
it was possible that this difference was not significant enough in absolute figures to influence 
previously exposed total costs results. The corresponding graphs are shown below: 
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Figure 14: Hospitalization-related total costs for stage III-IV patients. Figures indicated in parentheses 
correspond to (total patients; censored). A tick indicates censored patients. Cost data were not available for 8 
group A patients and 2 group B, who were treated as missing values. 
Monetary unit: CHF 
Median=78,960 (Group A) and 50,120 (Group B). Log-rank p=0.93 
 
Figure 15: Ambulatory total costs for stage III-IV patients. Figures indicated in parentheses correspond to 
(total patients; censored). A tick indicates censored patients. Cost data were not available for 8 group A 
patients and 2 group B, who were treated as missing values. 
Monetary unit: CHF 
Median=5,005 (Group A) and 8,537 (Group B). Log-rank p=0.006 
Thus, corroborating the ambulatory visits analysis, the two groups were shown to differ sig-
nificantly in terms of ambulatory costs. 
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DISCUSSION 
Two groups of patients suffering from advanced pancreatic cancer were chronologically 
defined, according to the first chemotherapy regimen with respect to the introduction of gemcit-
abine in Switzerland. The two groups were shown to differ significantly in terms of total survival 
time (median of 7.1 in group A versus 8.7 months in group B, p=0.012), ambulatory survival time 
(median of 4.8 in group A versus 6.6 months in group B, P=0.013), median per-patient chemo-
therapy doses received (1 in group A versus 14 in group B, p=0.0002), ambulatory visits in 
Oncosurgery (median of 21 in group A versus 28 in group B, p=0.007) and ambulatory costs 
(median of CHF 5,005 in group A versus 8,537 in group B, p=0.006). Patients having survived 
more than one year, i.e. “long-term survivors”, mainly accounted for the observed differences. 
There were no significant differences in terms of total hospitalization days as well as total and 
hospitalization-related costs. These results are discussed below in more details. 
METHODOLOGY 
The method employed to define a cut-off date and distinguish the two groups, according to the 
date of the first-line gemcitabine treatment for the first patient, was based on the following 
rationale: the availability of this drug and of subsequently introduced medications such as 
oxaliplatin, together with the significant improvements in clinical benefit responses that those 
new treatments made possible, was supposed to have changed the attitude of many oncologists 
regarding advanced pancreatic cancer management. As it is well corroborated by an exponential 
increase in the relevant medical literature since 1996 (which corresponds to the introduction of 
gemcitabine in the U.S.), chemotherapy was, from then on, considered as an efficient modality in 
advanced pancreatic cancer management, and was therefore more systematically prescribed. Our 
intention was to assess this change on a local cohort over the last decade along clinical dimen-
sions –i.e. mainly survival time– as well as medico-economic dimensions –i.e. costs incurred by 
the hospital. 
As far as diagnosis dates are concerned, the first day of the hospitalization stay leading to or 
confirming the diagnosis was systematically retained. This systematic approach was meant to 
allow for maximal precision in the definition of this crucial milestone. Given the rather large time 
span of the study, i.e. a decade, it can however not be totally excluded that evolution of diagnos-
tic procedures introduced some bias towards an artificially longer observed survival time for 
group B patients, an effect known as Will Rogers’ phenomenon [137]. By demonstrating metasta-
ses that would have formerly been silent and unidentified, more sensitive diagnostic technology 
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can result in stage migration: patients originally classified in less advanced stages could be 
assigned to a more advanced one. As a consequence, the prognosis of each stage cohort shall 
improve artificially because the less advanced stage cohort looses some of its worst cases (with 
silent more advanced disease) while the more advanced cohort shall be enriched by better prog-
nostic cases. The following figure illustrates this phenomenon: 
 
Figure 17: Will Rogers phenomenon; during the period corresponding to group B, patients with 
metastases that would have gone undiagnosed in group A could have been assigned to a stage III or IV due to 
progresses in diagnostic procedures, hereby increasing the overall prognosis in both stage I-II and stage III-IV 
subgroups 
Given the retrospective design of the present study, it is impossible to assess the importance of 
this effect in survival time estimations. However, apart from strictly technological evolutions in 
ultrasonography and CT-Scan techniques, there has not been any fundamental change of diag-
nostic strategy for pancreatic cancer in Geneva over the last decade, for example towards a more 
aggressive diagnostic behavior such as a screening process: patients were typically referred for 
jaundice or general alteration and subsequently underwent radiological procedures (typically 
ultrasound followed by CT-Scan) that led to the suspicion of a malignant process affecting pan-
creas. Diagnosis was then formally confirmed by histological examination of a tissue sample. 
Therefore, we believe the occurrence of a significant Will Rogers’ phenomenon is improbable in 
this particular setting. 
With respect to medico-economic analyses, several methodological limitations deserve special 
comments. First, the hospitalization cost calculation process relied mainly on the accuracy of 
medical coding at the end of each stay or ambulatory visit. Since coding was not yet assumed by 
professionals in Geneva but by care providers themselves, it may have sometimes been incom-
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plete or imprecise. Consequently, incurred costs may have been underestimated. However, eco-
nomic calculations can be considered as homogenous between the two groups, since they rely on 
the same cost accounting system, whose procedures have not fundamentally changed over the 
considered time period (1995-2003). Second, the method employed to express all cost in 2002 
units was correct, financially speaking. However, 2003 costs were expressed using the same 
weighting as 2002 ones, since economic data to compute the corresponding conversion factor 
were not available at the time of analysis. Similarly, information to compute weighting factors 
was not available prior to 1998, and a single factor was therefore used for years 1995 to 1997. 
Furthermore, weighting factors were corrected between 1999 and 2000, and the apparent reduc-
tion between those two years (weighting factor 1.08 versus 1.11) does not truly represent the real 
evolution of health care costs in Switzerland, which were rather steadily increasing from year to 
year. Although those limitations could have been circumvented by computing a compound annual 
growth rate between 1995 and 2002, we chose to use official factors, which reflect the apprecia-
tion by the hospital itself of its incurred costs. Last, ambulatory costs outside Oncosurgery were 
not included at all in cost analyses because corresponding data were not available retrospectively. 
However, Oncosurgery followed all included patients during their entire disease and it is unlikely 
that any significant expense occurred outside the hospital. Given those limitations though, med-
ico-economic results should more be considered more reflecting local experience of a particular 
hospital service than pretend to any generalization. 
CLINICAL RESULTS 
First, epidemiological information provided by the Geneva Cancer Registry showed that our 
study cohort was including approximately 16% of the total number of cases of pancreatic carci-
noma having occurred in Geneva from 1994 to 2001. Since such percentages are generally not 
published in the literature, it is difficult to comment on the representativeness of our sample 
compared to other studies. Interestingly, 32% of cases were considered as clinically malignant 
tumors without histological confirmation, which might reflect the difficulty in getting appropriate 
tissue samples in this pathology. 
Second, in terms of basic characteristics, the significant initial stage difference between the 
two populations at the time of diagnosis has already been mentioned in the methodology section. 
It was decided to restrict all subsequent analyses to stage III-IV patients to avoid biased survival 
time and medico-economic results: indeed, from a survival time perspective, resected patients 
have a clearly different biological evolution from those suffering from a more advanced disease 
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that precludes any surgical intervention. Also, from a medico-economic perspective, the two 
populations present a different cost structure, with resected patients incurring, for example, major 
expenses related to the initial surgery, while patients suffering from an advanced disease incur 
major expenses related, for instance, to mechanical intestinal or biliary complications. As already 
mentioned, a potential solution would have been to consider only the palliative phase of the dis-
ease for resected patients. However, starting point definition of this period was highly hazardous 
given the absence of any rigorously standardized follow-up procedures, both radiological and 
biological. Furthermore, on the biological side, it is well known that CA 19-9 level at the time of 
recurrence gives a much poorer indication than the initial TNM staging in terms of tumor load 
and prognosis. More generally, it does not make any clinical sense to stage patients at relapse for 
prognosis assessment purposes, making it almost impossible to assess patient homogeneity along 
this dimension. 
As far as stages are concerned, the proportion of locally advanced and metastatic pancreatic 
cancers between the two groups was comparable, and corresponds roughly to published results on 
larger series (proportion of about 1/3 to 2/3, respectively). With respect to other prognostic fac-
tors, the two populations were also homogeneous, with values corroborating previously published 
results (ECOG PS, median size of the primary tumor), except for a slightly higher proportion of 
body and tail locations for the primary tumor (30% in the present cohort versus around 20% in 
the literature). 
The subsisting significant difference between the two groups of stage III-IV patients in terms 
of age at initial diagnosis (median of 59 for group A and 66 for group B, p=0.005) was expected 
to favor group A in survival analyses. Given the limited influence of this factor in comparison to 
other prognostic variables and the survival results actually in favor of group B, stratified analyses 
were not conducted. Interestingly, this difference can be interpreted as reflecting behavioral 
changes among medical oncologists who, realizing the clinical benefit of newer chemotherapeutic 
molecules in this indication, might have proposed such treatments to a greater range of patients. 
Third and as expected from the retrospective design of the present study and from therapeutic 
management of included patients (usually outside any protocol), treatment modalities were rather 
inhomogeneous. For instance, due to the method employed for defining the two groups, it was 
unavoidable that some patients belonging to group A had actually received a few cycles of gem-
citabine at some point of their management, since they sometimes survived several months after 
1998, i.e. after this drug had been made available. However and by definition, patients in group A 
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never received gemcitabine as a first-intent therapy, while it was the case for every group B 
patient. Overall, the evolution of chemotherapy prescribing practice in Geneva over the last dec-
ade can be summarized as follows: in group A, the most often administered treatment consisted 
of 5-FU and leucovorin-based regimens (total of 42 doses). In group B, contrastingly, the most 
often administered fist-line regimen consisted of an association of gemcitabine and capecitabine 
(which simulates a continuous infusion of 5-FU; total of 331 doses administered), with second-
line regimens generally associating 5-FU and leucovorin (total of 120 doses administered) or 
oxaliplatin and irinotecan (total of 52 doses administered). The total number of per-patient doses 
was significantly different between the two groups, probably related to the corresponding differ-
ence in survival time (patients in group B enjoyed a prolonged survival time compared to patients 
in group A, which allowed them to receive more cycles) and to behavioral changes among medi-
cal oncologists towards prescribing chemotherapy more systematically in this indication. 
Fourth, in terms of survival analysis, we observed a statistically significant difference in favor 
of group B patients (median survival time of 214 days or 7.1 months in group A versus 262 days 
or 8.7 months in group B, p=0.012, hazard ratio=0.52, 95% CI 0.23-0.84), despite the age profile 
discrepancy, which was favorable to group A. Large and overlapping 95% confidence intervals 
reflect the small size of the samples. Therefore, the observed significant difference should more 
be considered as a positive trend. However, recalling previously exposed data from several 
reviews [50-58], this trend is in line with average values published so far in the literature, respec-
tively for 5-FU-based regimens (which were the main treatment in group A patients) and for 
gemcitabine-5-FU combinations (which were the first-intent treatment for a vast majority of 
patients in group B). Interestingly, the difference was mainly accounted for by the long-term sur-
vivor fraction of patients in group B, which can be better appreciated by considering 1-year sur-
vival probabilities (14% in group A versus 40% in group B; overlapping 95% confidence inter-
vals: [3-35%] in group A versus [24-58%] in group B). As it is well corroborated by the litera-
ture, gemcitabine as well as some other new molecules available for advanced pancreatic cancer 
management seem to particularly benefit those patients whose tumor biology tends to respond to 
chemotherapy. Patients belonging to this specific category now survive longer, sometimes even 
much longer than the average 9 months mentioned in medical textbooks. It is however possible, 
given the small groups in the context of our study, that a difference in proportion of different 
tumor biology profiles included in groups A and B introduced an unidentified bias in survival 
analyses and partly accounted for the observed difference. It is also possible, as is suggested by 
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the older age of patients from group B at the time of diagnosis, that the overall epidemiology of 
pancreas cancer (i.e. its biological characteristics) changed over the past few years and accounted 
for the observed difference. In absence of supporting evidence in today’s medical literature, this 
would require further investigations. 
Fifth, in terms of total hospitalization days, the two groups were comparable, indicating that 
patients in group B, although having survived longer, did not experience significantly more hos-
pital stays than in group A. This was further evidenced by comparing the two groups in terms of 
ambulatory survival (calculated as total survival time minus hospitalization days for each 
patient), which was shown to be significantly different (median of 144 days or 4.8 months in 
group A versus 199 days or 6.6 months in group B, p=0.013). According to the hospitalization 
category analysis (table 11), patients suffering from advanced pancreatic cancer were mainly 
hospitalized for serious disease-related complications as well as for terminal palliative care. In 
this context, the absence of difference in hospitalization days between the two groups suggests 
that the increase in total survival time was accompanied by a relative preservation in terms of 
quality of life, patients having been able to spend more time in their usual environment, followed 
on an outpatient basis. Consequently, on the ambulatory side, the significant difference between 
the two groups in terms of visits to the outpatient clinic for treatment or check-up is probably 
related to the difference in survival time: patients in group B, who survived longer, were also 
followed periodically, and they received more chemotherapy cycles than in group A, as previ-
ously exposed. Intuitively, this pattern had to be similar in terms of medico-economic analyses. 
MEDICO-ECONOMIC RESULTS 
The two groups were not significantly different in terms of total costs incurred by the hospital. 
However, when costs were broken down into hospitalization-related and ambulatory-related cate-
gories, a significant difference was evidenced for ambulatory costs, which corresponded for pan-
creatic cancer mainly to outpatient visits for treatment, check-up and general management. Those 
expenditures were significantly higher for patients in group B than in group A (median of CHF 
8,537 versus 5,005; p=0.006). Considering absolute figures, the low proportion of total costs rep-
resented by the ambulatory category probably explains why, given the small size of the samples, 
this difference was not reflected in global analyses (this proportion was 6% in group A and 
increased to 15% in group B). In line with the previously observed difference in per-patient 
administered chemotherapy doses as well as in the number of ambulatory visits to Oncosurgery, 
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these results are probably related to the increased survival time of group B patients, who were 
followed and treated longer than in group A, without being hospitalized more often. 
We are aware that the low number of patients for whom economic data were available (par-
ticularly in group A, n=14) somewhat jeopardizes our results from a statistical standpoint, and 
hence that the latter can at best be considered as indicating a tendency. They are however worth 
mentioning because the trend they suggest could be further assessed prospectively, and because 
they rely on a methodology that draws strongly upon the Geneva teaching Hospital’s cost 
accounting system, which could be more extensively used for such medico-economic analyses in 
the future. 
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CONCLUSION 
Several biases related to the retrospective design of the present analyses might limit their 
scope and preclude them to be considered as general. Therefore, this study should be interpreted 
in its local and exploratory context. Results exposed, and particularly medico-economic observa-
tions, need to be validated in prospective studies of larger scope. But taken all together, our 
results suggest the following interpretation: since late 1998, a more standardized and systematic 
prescription of new chemotherapeutic drugs in advanced pancreatic cancer benefited a small per-
centage of responders in terms of survival time, although the quantitative absolute increase was 
minor. Furthermore, if the number of hospitalization days is accepted as a rough proxy for the 
quality of life, those responders seem not to have experienced significantly more debilitating 
complications in absolute terms. On the contrary, they were managed for a relatively long period 
on an ambulatory basis, periodically consulting the outpatient clinic for treatment and general 
check-ups. These observations suggest that in the future, along with the development of more 
effective molecules and their systematic assessment in combination regimens, some patients suf-
fering from advanced pancreatic cancer may experience a prolonged relief of symptoms. 
From an economic perspective, however, every progress has its cost. In that sense, present 
medico-economic results should not be underestimated: prolonging survival time in patients suf-
fering from an advanced malignant disease that cannot be cured inevitably leads to prolonged 
treatment and follow-up, and repeated biologic and radiological investigations. In the case of 
advanced pancreatic cancer, given the dismal prognosis, ambulatory costs may not sound impres-
sive in absolute figures, although some individuals reached a range of CHF 20,000 to 50,000 of 
ambulatory costs in the present cohort. However, extrapolating those figures to the entire Swiss 
population gives a much clearer idea of the financial implications of medical progresses that may 
seem minor at passing glance. Also, considering other much more prevalent advanced malignant 
diseases helps understand this dilemma from the centrality it currently occupies in politicians’ 
and economic stakeholders’ minds. A particularly good example is metastatic colorectal cancer, 
where chemotherapy evolved significantly over the last decade, from 5-FU modulated by leuco-
vorin to poly-chemotherapy regimens (fluoropyrimidines with oxaliplatin or irinotecan) inte-
grated into multi-disciplinary therapeutic strategies. As a result, median survival time of patients 
with metastatic colorectal cancer currently ranges between 17 and 22 months [138], during which 
they have to be treated with expensive association regimens, together with check-ups and peri-
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odic reassessments. Benefits to those patients are beyond contest compared to the situation ten 
years ago, when median survival time figures were approximately half the current ones (between 
10 and 12 months). But those benefits have a cost. It was recently estimated that the doubling of 
median survival time achieved over the past decade has been accompanied by a staggering 340-
fold increase in drug costs –just for the initial eight weeks of treatment (approximately $100-300 
for fluorouracil-based regimens to $20,000-30,000 for bevacizumab or cetuximab via $10,000 for 
irinotecan or oxaliplatin) [139]. Thus, medication costs for the initial eight weeks of treatment for 
the estimated 56,000 colorectal cancer patients diagnosed at stage IV or developing metastases in 
2004 in the United States were estimated in the range of $666 million to $1.2 billion (with the 
addition of monoclonal-antibody therapy). 
Health care is fascinating in that it incorporates two crucial dimensions of quality of medical 
services and economic efficiency, which are often considered as antagonist or incompatible. This 
multidimensionality is probably the reason why it cannot obey a single liberal economic model 
and why it is currently characterized by a complex and country-specific mixture of regulations 
and market-openness, whose ideal proportions have yet to be defined. That health care-related 
costs are steadily increasing in developed countries is a fact, as is the necessity of addressing this 
situation. However, it is also a fact that people overall are more and more expecting and 
demanding medical excellence. Ultimately, trade-off between quality and economic burden is a 
choice each society as a whole has to make for itself. This choice implies communication and 
concord between all involved stakeholders –regulators, payers, providers and above all patients. 
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